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ABSTRACT: Significantly more potent second generation 4-amino-7-chloroquinoline (4,7-ACQ) based inhibitors of the
botulinum neurotoxin serotype A (BoNT/A) light chain were synthesized. Introducing an amino group at the C(3) position of
the cholate component markedly increased potency (IC50 values for such derivatives ranged from 0.81 to 2.27 μM). Two
additional subclasses were prepared: bis(steroidal)-4,7-ACQ derivatives and bis(4,7-ACQ)cholate derivatives; both classes
provided inhibitors with nanomolar-range potencies (e.g., the Ki of compound 67 is 0.10 μM). During BoNT/A challenge using
primary neurons, select derivatives protected SNAP-25 by up to 89%. Docking simulations were performed to rationalize the
compounds’ in vitro potencies. In addition to specific residue contacts, coordination of the enzyme’s catalytic zinc and expulsion
of the enzyme’s catalytic water were a consistent theme. With respect to antimalarial activity, the compounds provided better
IC90 activities against chloroquine resistant (CQR) malaria than CQ, and seven compounds were more active than mefloquine
against CQR strain W2.
■ INTRODUCTION
Antimalarial compounds consisting of two 4-amino-7-chloro-
quinoline (4,7-ACQ) components linked by flexible tethers
were identified as some of the first small molecule botulinum
neurotoxin serotype A light chain (BoNT/A LC) inhibitors.1
Shortly thereafter, we discovered that antimalarial agents
composed of a 4,7-ACQ component coupled with either an
adamantane or a cholic acid derived component provided
effective dual inhibitors of the BoNT/A LC and Plasmodium
falciparum strains D6 and W2 strains.42,43 This discovery led to
a model in which 4,7-ACQ-based antimalarials are/have been
modified with the intent of also generating novel BoNT/A LC
inhibitors and vice versa.47 Accordingly, we continued to
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synthesize new derivatives to probe structure−activity relation-
ships for such chemotypes and to generate more potent
BoNT/A LC inhibitors that, because they incorporate a 4,7-
ACQ moiety, would be expected to be prospective antimalarial
agents.
Botulinum neurotoxins (BoNTs), exotoxins secreted by
anaerobic, spore-forming bacterium Clostridium botulinum, are
the most potent of biological toxins.2 BoNTs are responsible
for the potentially fatal disease botulism, which is most com-
monly associated with food contamination, wound infection,
and colonizing infection in infants. However, because of ease of
production, dissemination,3 lethality,4 and amenability for use
as biological weapons,5 BoNTs are classified as category A bio-
threat agents by the Centers for Disease Control and Prevention
(CDC).
There are seven known BoNT serotypes (identified as
A−G). Each cleaves a specific peptide bond in one or more of
three proteins that form the soluble N-ethylmaleimide-sensitive
factor attachment protein receptor (SNARE complex).6,7 The
interaction of these three proteins facilitates the transport of
acetylcholine into neuromuscular junctions. Botulinum neuro-
toxins are secreted as single polypeptide chains and, following
post-translational processing, are composed of a heavy chain
(HC) subunit and light chain (LC) subunit; the two subunits
are covalently linked by a disulfide bridge.8,9 The HC,
which comprises two domains of ∼50 kDa, is responsible for
mitigating toxin internalization and release into the neuronal
cytosol via an acidic endosome. The C-terminal domain
(i.e., the ganglioside and protein receptor-binding domain)
binds to the neuronal cell membrane and mediates the
internalization of toxin containing endosomes; the N-terminal
domain facilitates the release of the LC from the endosome into
the cell cytosol. The LC is a zinc-dependent metalloprotease
that cleaves SNARE proteins. This proteolysis eliminates
neurotransmitter release into the synaptic cleft, thereby causing
the flaccid paralysis that is medically diagnosed as botulism.
BoNT serotypes A and E cleave synaptosomal-associated
protein of 25 kDa (SNAP-25).10 Serotypes B, D, F,11 and G
cleave vesicle-associated membrane protein,12 and serotype C1
cleaves both SNAP-25 and syntaxin.13
The BoNT/A LC is the most potent and longest acting of
the BoNT LC serotypes in the neuronal cytosol.14 For example,
the BoNT/A LC is 106-fold more potent than cobra toxin
and 1011-fold more deadly than cyanide. The lethal dose of
BoNT/A holotoxin is estimated to be between 1 and 5 ng kg−1
for humans.15 Currently, there are no small molecule thera-
peutics available to treat botulism. And while antibody-based
vaccines are available,16 this avenue of treatment is limited by
a short window of therapeutic opportunity, since such
biomolecules cannot penetrate into the cell cytosol.4 Hence,
developing small molecules that will effectively inhibit BoNT
LC proteolytic activity postneuronal intoxication is of particular
interest.
A variety of BoNT/A LC inhibitors have been reported17
and range from compounds bidentate coordinating the enzyme
catalytic Zn2+18 to allosteric inhibitors.19 In general, the most
potent BoNT/A LC inhibitors reported to date possess Ki
values ranging from 0.1 to 10 μM and include hydroxamic acid
based compounds 1 and 3,20 2,5-diphenylthiophene derivative
2,21 betulin derivative 4,22 naphthopyrone 5,23 and chrysene 624
(Chart 1).
Malaria is a devastating global health threat, with nearly half
of the world population at risk of being infected.25 Malaria is
caused by five Plasmodium species: P. falciparum, P. ovale, P.
vivax, P. malarie, and P. knowlesi, of which P. falciparum, which
causes cerebral malaria, is the major cause of mortality. Malaria
parasites contain an acidic food vacuole (FV) that digests
hemoglobin (Hb), and it is generally accepted that the FV is
the site of action for a number of aminoquinoline (ACQ) based
drugs. The heme obtained from Hb degradation is toxic to the
Chart 1. Structures of Potent BoNT/A LC SMNPIs
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parasite and is therefore transformed into insoluble hemozoin
pigment, while the globin is hydrolyzed into individual amino
acids. Antimalarial drugs that are active within the FV appear to
kill the parasite by either producing toxic free radicals26 or
blocking hemozoin formation, as in the case of ACQ-based
drugs.27 The development of widespread drug resistance to
chloroquine (9, CQ, Chart 2), one of the most successful
antimalarial drugs, has resulted in severe health issues for
countries in malaria endemic regions. Although collected data
indicate that mutations in the P. falciparum CQ-resistant trans-
porter (PfCRT), multidrug resistance protein 1 (PfMDR1),
and multidrug resistance-associated protein (PfMRP) are
responsible for malaria parasite resistance to CQ and its
analogues,28 additional analyses appear necessary to fully
corroborate such data.29 Therefore, significant focus has been
placed on the syntheses of peroxide antimalarials,30 as well as
on the development of other chemotypes that prevent heme
polymerization.31 Nevertheless, various ACQ-based derivatives
are being investigated for their antimalarial activity, either
since they appear highly active and nontoxic, such as
pyrrolizidine-ACQ compounds32 and aminoquinoline AQ-
13,33 or because of their contribution to the development of
SAR, for example, compounds such as 4-N-, 4-S-, or 4-O-
alkylaminoquinoline derivatives.34 Hybrid adducts of various
biologically active compounds covalently bonded to the ACQ
moiety,35 such as reversal agents,36 complexes with Au and
Ru,37 antibiotic azithromycin,38 2-imidazolidine and ferrocenyl
derivatives,39 and tetraoxanes,40 are of special interest. Very
recently, a breakthrough in the antimalarial field has been
achieved: quinolone antimalarials that target the parasite’s liver
and blood stages, as well as forms that are crucial to disease
transmission, have been reported.41
As indicated above, we previously described the synthesis and
inhibitory activity of BoNT/A LC inhibitors possessing a 4,7-
ACQ moiety covalently tethered to either a cholic acid derived
or an adamantane component. The compounds were database
mined using a pharmacophore for BoNT/A LC inhibition42
and were originally synthesized as antimalarial agents. Examples
include 7, 8, and 10 (Chart 2). In vitro testing indicated that
the compounds inhibit the BoNT/A LC with IC50 values in the
low micromolar range. Furthermore, it is important to note that
several of the derivatives provide potent antimalarial activity
against CQR strain W2 and multidrug resistant strain (MDR)
TM91C235.43 For example, 7 was very active in vitro against
P. falciparum CQR and CQ susceptible (CQS) strains, with a
resistance index (RI (W2/D6)) of 0.65.43 This compound also
cured mice infected with P. berghei in a Thompson test.44
Herein, we present second generation 4,7-ACQ-cholate
based inhibitors of the BoNT/A LC that are significantly
more potent than initially discovered leads.42,43 In particular,
we expanded our understanding of the SAR for this inhibitor
chemotype via the generation of compounds with a variety of
substitutions on the C(3) position of the cholic acid com-
ponent. In addition, it was anticipated that such an approach
would facilitate the synthesis of bis(4,7-ACQ)-cholic acid deriv-
atives, which became desired target molecules (based on the
promising activities of compounds 7, 8, and 12 (Scheme 1).42
Finally, because initially discovered derivatives of the 4,7-ACQ-
cholic acid chemotype were originally developed as antimalarial
agents, the compounds prepared during this study were also
examined for potency against three P. falciparum strains.
Overall, the unique capacity of this general chemotype to
provide both inhibition of the BoNT/A LC and antimalarial
activity provides a paradigm that facilitates the repositioning of
derivatives based on target potency.
■ RESULTS AND DISCUSSION
The ability of derivative 12 (Scheme 1) both to inhibit the
BoNT/A LC42 and to act as an antimalarial agent43 prompted
the development of a new generation of 4,7-ACQ-cholic acid
based derivatives. The design of the compounds focused on
investigating effects on potency resulting from (1) an additional
basic group at position C(3) of the cholic acid component, (2)
the incorporation of a second ACQ component, and (3) the
length of the α,ω-diaminoalkylidene spacer between the steroid
and 4,7-ACQ moiety(ies). Furthermore, functionalization of
the C(3) basic group (acylation, mesylation, and alkylation), as
well as changes in the basic character of the substituent (i.e.,
H-bond donor/acceptor strength and voluminosity), was
examined in the context of inhibitory activity and metabolic
stability. To aid in rationalizing differences in the in vitro
potencies of the derivatives, detailed docking simulations were
performed in the BoNT/A LC substrate cleft. In addition,
assessment of the in vitro antimalarial activities of the new
derivatives against the CQS and CQR strains of P. falciparum
was also conducted, and the most active antimalarial of the
series was examined in a P. berghei rodent model.
Chart 2. Structures and Activities of BoNT/A LC Inhibitors Possessing an ACQ Moiety
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Synthesis. The syntheses of the target compounds are
presented in Schemes 1−6. Derivatives 12−15 were synthe-
sized using a previously described procedure.43 Hydrolysis of
the acetate at C(3) afforded corresponding alcohols 16−19,
which were further oxidized with IBX in DMSO in the presence
of TFA to ketones 22−25 (Scheme 1). Derivatives 12 and 13
were selectively N-methylated using 37% formaldehyde and
NaBH(OAc)3.
Key intermediates for the synthesis of N-alkylated congeners
36−57, i.e., compounds 33−35, were obtained from precursor
2645 (Scheme 2). In the first step, the free amine was protected
as an acetate, mesylate, or Boc derivative (27, 28, or 29,
respectively). Subsequently, selective hydrolysis and reduction
of the intermediate mixed anhydrides (reaction steps b and c,
respectively) (Scheme 2) afforded compounds 33−35 in
54−80% overall yield. The three intermediate compounds were
subsequently transformed (via the above indicated procedure)
using N-(7-chloroquinolin-4-yl)ethane-1,2-diamine (ACQ2) or
N-(7-chloroquinolin-4-yl)propan-1,3-diamine (ACQ3) into
respective derivatives 36−41 (Scheme 3).
Scheme 2a
a(a) Ac2O/Py, rt, or MsCl/DCM/Et3N, rt, or Boc2O/DCM/Et3N, rt; (b) NaOH/i-PrOH, 80 °C; (c) (i) ClCO2Et/Et3N/DCM, rt, 3 h; (ii) THF/
DCM/MeOH, NaBH4, rt.
Scheme 1a
a(a) (i) PCC/DCM, rt; (ii) ACQ2, ACQ3, ACQ4, or ACQ6, NaBH(OAc)3, DCM, rt; (b) K2CO3, MeOH, rt, 3 h; (c) IBX, DMSO, TFA, rt, 6 h;
(d) HCHO, NaBH(OAc)3, DCM, rt.
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N-Mesyl and N-Boc derivatives 38−41 were methylated
using 37% formaldehyde to yield 42−45, respectively. After
removal of the N-Boc protecting group, permethylated prod-
ucts 56 and 57 were obtained in two steps from 44 and 45,
respectively. On the other hand, 40 and 41 were transformed
into 3α-(N,N-dimethyl) derivatives 50 and 51 by protective
group manipulation using Fmoc and Boc protection groups
(Scheme 4). Finally, derivatives 52 and 53, which contain primary
amino groups, were obtained from 40 and 41 via the removal of
the N-Boc group with 50% TFA in DCM (Scheme 3).
In the above reductive amination of the aldehyde derived
from 35 with ACQ2 or ACQ3, bis-steroidal 4,7-ACQ deriv-
atives 58 and 59 were also isolated as double alkylation by-
products (Scheme 5). Bis-steroidal 4-aminoquinoline derivatives
60 and 61, which possess free amino groups at position C(3),
were obtained after the deprotection of 58 and 59, respectively.
Additional targets of the present work, bis-4,7-ACQ deriv-
atives 62−68 (Scheme 6), were obtained as diastereomers at
C(3) from 24-ACQ-ketones 22−25 (Scheme 1) via reaction
with respective ACQ-amines. However, the products were ob-
tained in rather low yield, and derivatives with shorter linkers,
i.e., 62 and 63, having two and three methylene groups, respec-
tively, were not separated into single isomers and were there-
fore tested in the biological assays as mixtures.
The structures of all synthesized compounds were confirmed
by spectral and analytical techniques. The purity of all tested com-
pounds was determined with Waters and Agilent HPLC instru-
ments and was ≥95% for all. Analytical details are provided in the
Experimental Section and Supporting Information.
Inhibition of the BoNT/A LC. The inhibitory efficacies of
derivatives 12−68 at 20 μM, employing a well-established
HPLC-based assay for BoNT/A LC inhibition,46 are shown in
Table 1. The assay uses a synthetic substrate that contains the
SNAP-25 scissile bond (SNAP-25 residues 187−203 of SNAP-
25), and proteolytic activity is determined via comparison of
the peak areas of the products versus the intact substrate.57 In
Scheme 3a
a(a) (i) PCC, DCM, rt, 3 h; (ii) ACQ2 or ACQ3, NaBH4/MeOH or NaBH(OAc)3/DCM, rt, 6 h; (b) HCHO, DCM, NaBH(OAc)3, rt, or HCHO,
MeOH, ZnCl2, NaBH3CN, rt; (c) TFA/DCM, rt; (d) HCHO, MeOH, ZnCl2, NaBH3CN, rt; (e) TFA/DCM, rt, 3 h.
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the assay, CQ exhibited only marginal inhibition of the BoNT/
A LC (6.51% at 20 μM), which clearly emphasizes the importance
of the cholic acid component;47 the cholic acid component not
only contributes to the overall amphiphilic character of the in-
hibitors but also results in additional interactions with amino acid
residues in BoNT/A LC binding cleft (vide infra).
The first set of inhibitors (12−15) was prepared to evaluate
the effect on activity of increasing the length of the methylene
bridge between the steroid core and the 4,7-ACQ component;
the results indicated that increasing the length of the methylene
bridge did not significantly affect inhibitory potency. More-
over, the results indicated that within the ACQ2 (compounds
12, 16, 22), ACQ3 (compounds 13, 17, and 23), and N-(7-
chloroquinolin-4-yl)hexane-1,3-diamine (ACQ6, compounds
15, 19, and 25) series, transformations at C(3) from Ac to
OH to CO generally diminished the inhibitory activities of
Scheme 4a
a(e) Fmoc-Su, DCM, rt, 4 h; (f) TFA/DCM, rt; (g) (i) HCHO,MeOH, ZnCl2, NaBH3CN, rt, 24 h; (ii) Pyp/DCM, rt, 24 h.
Scheme 5a
a(a) (i) PCC, DCM, rt; (ii) ACQ2 or ACQ3, NaBH(OAc)3/DCM; (b) TFA/DCM, rt.
Scheme 6a
a(a) ACQ2, ACQ3, ACQ4, or ACQ6, NaBH3CN/MeOH, rt.
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the respective compounds. N-(7-Chloroquinolin-4-yl)butane-
1,3-diamine (ACQ4) derivatives (compounds 14, 18, and 24)
were the exception. Among derivatives with nonbasic sub-
stituents at C(3) (Scheme 1), the most active were acetate 13
(IC50 = 2.28 μM) and keto derivative 23 (IC50 = 2.32 μM).
The introduction of a basic amino substituent at the C(3)
position of the steroid component markedly increased in-
hibitory potency. Among this set of compounds, the most
active was ACQ2 derivative 52, which contains an NH2 group
at the C(3) position and a secondary amino group at the C(24)
position (IC50 = 0.81 μM). The activity of this compound was
followed by ACQ2 derivative 50 (IC50 = 1.02 μM), which
possesses a tertiary amine at the C(3) position. The observed
results suggest that for potent BoNT/A LC inhibitory activity
the presence of an ionizable amino group at the C(3) position
is critically important. The least active compounds are cholic
acid derivatives with acidic NH groups (i.e., N-Ms and N-Boc)
at C(3) (see 42 (IC50 = 24.97 μM) and 44 (IC50 = 6.78 μM));
both are ACQ2 derivatives. For derivatives in which amino
groups at C(24) and/or C(3) were methylated, BoNT/A LC
inhibitory activity was not significantly affected (for compar-
isons see 52 → 54, 53 → 55, 54 → 56, and 55 → 57).
It has been shown that the catalytic cleft of the BoNT/A LC
is very plastic48 because of the mobility of flexible loop regions.
Hence, we hypothesized that the cleft can conformationally
adapt to accept large molecules,49,50 Consequently, we
examined two additional subclasses: bis-steroidal 4,7-ACQ
derivatives (58−61) and bis-4,7-ACQ cholic acid derivatives
(62−68). Both groups of sterically demanding inhibitors
substantially enhanced inhibition. A significant increase in in-
hibitory activity was observed after removal of the N-Boc
protecting group, 59 (6%) vs 61 (93%, IC50 = 0.63 μM), which
confirmed the importance of the presence of a basic amino
group at C(3) for good activity. The bis-4,7-ACQ derivatives all
inhibited the enzyme by ≥95% at 20 μM and retained
comparable levels of potency at 10 μM (see Table 1S in
Supporting Information). The Ki values of these derivatives
were found to be lower than 0.4 μM, with compound 67 being
the most potent derivative (Ki = 0.103 μM).
As an important step in further evaluating the inhibitors,
three derivatives that were found to enter cells were examined
for the ability to protect SNAP-25 during BoNT/A challenge in
primary neurons (Table 2). Western blot analysis was used to
determine the relative concentrations of intact and cleaved
SNAP-25 in treated and control cells. The experiments were
performed using 1.5 μL of a 10 mM concentration of ligand in
the presence of 10 μL of a 50 nM solution of BoNT/A. The
results indicate that 3-amino derivative 52 significantly protects
SNAP-25 versus corresponding 3-(N-acetyl) derivative 36
(77 % vs 16 %, respectively), further confirming the importance
of a basic amino substituent at cholic acid position C(3). Some-
what better results were obtained with bis-steroid derivative 60.
In the presence of 5 μL of a 100 nM solution of antibiotic
bafilomycin (Baf) SNAP-25 protection is slightly higher (77%
with 52 only and 88% upon Baf addition vs 60 (89% alone and
96% upon 5 μL of Baf (100 nM) addition)). Using 25 μL of a
100 nM solution of Baf provided no further increase in pro-
tection. The results suggest that 4,7-ACQ-cholate-based inhibitors
Table 1. In Vitro Inhibitory Activity of Tested Compounds against BoNT/A LC
BoNT/A LC
compd % inhibitiona IC50 (μM) Ki (μM)
e
NSC 240898b 73.31c 2.62
12 74.00 3.80 6.99 ± 0.46
13 81.43 2.28 5.67 ± 0.37
14 69.04
15 83.35
16 69.44 4.68
17 69.88 5.18
18 80.83
19 62.88
22 67.09 5.70
23 72.86 2.32
24 81.45
25 77.23
20 33.28 34.51 ± 4.72
21 61.07 4.48 7.69 ± 0.39
36 73.95 2.46
37 77.30 4.92
38 74.38 5.09
39 72.92 3.25
40 67.37 4.90
41 74.91 3.24
42 33.75 24.97
BoNT/A LC
compd % inhibitiona IC50 (μM) Ki (μM)
e
43 55.64 8.21
44 29.97 6.78
45 59.63 6.62
50 93.51 1.02
51 92.59 1.34
52 89.34 0.81 3.22 ± 0.32
53 84.80 1.04 3.45 ± 0.35
54 89.48 1.14
55 81.38 1.13
56 85.54 2.27
57 86.86 1.29
60 82.22 3.05
59 6.42
61 92.81 0.63
62 96.47 0.341 ± 0.042
63 97.24 0.171 ± 0.013
64 96.68 0.300 ± 0.065
65 89.57 0.389 ± 0.059
66 95.46 0.285 ± 0.056
67 95.43 0.103 ± 0.024
68 93.70 0.300 ± 0.059
9d 6.51
aPercent inhibition calculated at 20 μM. Percent inhibition measurements were performed in duplicate, and standard deviations were less than
(25%) for all. IC50 calculations were determined by measuring enzyme activity at nine different SMNPI concentrations and in the absence of the
small molecule. The small molecule concentrations used in the measurements were determined by estimating the IC50 value and moving in 1 log
increments in either direction of the estimated value. bNSC240898, used as the control for comparison, displayed dose dependent inhibition of
BoNT/A induced SNAP-25 cleavage in neurons with no toxicity at concentrations as high as 40 μM (ref 57). cAverage value from more than
20 measurements. dTested as diphosphate salt. eFor Ki determination, reaction velocity versus substrate concentration was plotted for multiple small
molecule concentrations. These plots were analyzed using global kinetic analysis. Subsequently, the data were fit to a model of competitive inhibition
and analyzed by nonlinear regression analysis.
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can successfully protect SNAP-25 in the presence of the
BoNT/A holotoxin, with a slight additive effect when given in
combination with Baf (a universal antagonist of all BoNTs in
cell culture that acts by inhibiting the release of the LC into the
neuronal cytosol3).
Docking Simulations. To rationalize the inhibitory potencies
of the new derivatives, structure-based docking simulations were
performed using Schrödinger Suite 2011 and the modules
therein.51 The structure of the BoNT/A LC used in this study
was obtained from X-ray crystal structure PDB code 3DS9.52
For compounds 12−57, which are composed of a single
steroid and ACQ component, all docking studies indicated
that a carbonyl oxygen from the acetoxy (AcO-) group at C(7)
(steroid numbering) coordinates the enzyme’s Zn2+ (Figure 1)
while concomitantly expelling the catalytic water. This
effectively disables the enzyme’s proteolytic activity (see ligand
interactions diagrams, Figures S1−S3). Importantly, this is a
main difference versus previously described models in which no
coordinate interaction with the Zn2+ was observed.42 Strong salt
bridges and H-bonds between the N-C(24) ammonium cations
of the ligands (i.e., from secondary or tertiary nitrogens) and
Glu164 and/or Glu55 (Figure 1; see also Figure S1) were
observed. Specifically, derivatives possessing secondary ammonium
cations engaged in interactions with both Glu164 and Glu55,
while derivatives with tertiary ammonium cations, because of steric
hindrance, interacted with only with Glu55. These results appear
to rationalize the improved inhibitory potencies of compounds
possessing secondary ammonium cations versus derivatives with
tertiary ammonium cations but which possess the same substituent
at the C(3) position: 12 (74.00%) vs 20 (33.28%); 53 (84.80%,
IC50 =1.04 μM) vs 55 (81.38%, IC50 =1.13 μM); 52 (89.34%,
IC50 = 0.81 μM) vs 54 (89.48%, IC50 = 1.14 μM).
Another key interaction observed for inhibitors 12−57 was
a strong cation−π interaction between the ligand’s 4,7-ACQ
moiety and Arg231, with surrounding residues forming a
pocket in which the aromatic component engages in hydro-
phobic collapse (Figures S1−S6).
Favorable interactions were also observed between sub-
stituents on the C(3) positions of the inhibitors’ cholic acid
components and proximal residues. Importantly, these interac-
tions appear to be heavily weighted with respect to rationalizing
the inhibitory efficacies of ligands having neutral and basic
C(3) substituents. Ligands with acetoxy and hydroxy groups
can engage in an H-bond with Tyr366 (Figure S1 and Figure S2).
Moreover, the methyl group from the acetoxy substituent may
additionally stabilize the ligand−enzyme binding event through
hydrophobic interactions with Phe369 and Tyr366. Hence,
these interactions explain the more efficacious inhibition provided
by the 3-acetoxy vs 3-hydroxy derivative (cf. 12 vs 17). Ligands
possessing a C(3) amino group engage in favorable salt bridges
and H-bonds with Glu252 and/or Asp370 (Figure 1; see also
Figures S1 and S3). Ammonium cations derived from primary
amino groups engage in interactions with both amino acid
residues (52, 53, 54, and 55), while derivatives with tertiary
nitrogens achieve interactions with only Asp370 (50, 51, 57,
and 56). These strong electrostatic interactions could explain
the increase in activity for the ligands with basic C(3) sub-
stituents when compared to noncharged substituents. Fur-
thermore, ligands with primary ammonium cations can form
two stabilizing interactions, while those with tertiary
ammonium cations can engage in only one salt bridge. This
is in accord with their activities and explains why compounds
with the same substitution at C(24) follow the same relative
activity patterns: 52 (IC50 = 0.81 μM) vs 50 (IC50 = 1.02 μM);
54 (IC50 = 1.14 μM) vs 56 (IC50 = 2.27 μM). The same
relationship was also observed for compounds from the ACQ3
series, e.g., 53 (IC50 = 1.04 μM) vs 51 (IC50 = 1.34 μM).
The above observations can also explain the change in inhibitory
activity in the sequence 52 → 50 → 56. In this series of ligands,
the introduction of methyl groups on positions C(24) and C(3)
leads to a decrease in interaction strength with acidic residues and
consequently to a decrease in the activities of the ligands. The
experimental results seem to further support the models based on
observed decreases in the activities of ligands possessing BocNH
or MeSO2NH groups (42, 44 vs 54, and 43, 45 vs 55).
Next we examined derivatives possessesing 4,7-ACQ substitu-
ents linked to both positions C(3) and C(24) of the steroidal core.
One series possesses an α-bonded ACQ substituent at C(3) (66
and 68, Figure S4), and the other possesses a β-bonded ACQ at
C(3) (64, 65, and 67, Figure 2; see also Figure S6). The simula-
tion results indicate that compounds of the α-C(3) series, i.e., 68
and 66, oriented similarly to the members of the mono-ACQ series
but with some emerging differences. Most distinctive was a lack of
any interactions by the amino group at C(3). For these ligands,
Table 2. Protection of SNAP-25 by Steroidal SMNPIsa
% of intact SNAP-25
compd A B C
36 16 28 36
60 89 96 93
52 77 88 81
blank 31b 40 43
aA: 488.5 μL of medium + 1.5 μL (10 mM) of compound + 10 μL of
BONT-A (50 nM). B: 483.5 μL of medium + 1.5 μL (10 mM) of
compound + 5 μL of Baf (100 nM) + 10 μL of BONT-A (50 nM). C:
463.5 μL of medium + 1.5 μL (10 mM) of compound + 25 μL of Baf
(100 nM) + 10 μL of BONT-A (50 nM). Blank: 490 μL of medium +
10 μL if BONT-A (50 nM). bAverage value from four measurements.
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three points of binding are most interesting: (1) the carbonyl
oxygen of the α oriented acetoxy group at C(7) coordinates the
enzyme’s Zn2+ (Figure S4); (2) a salt bridge interaction between
the protonated amino group at C(24) and Glu164; (3) a subset
involving favorable hydrophobic contacts between the 4,7-ACQ
component tethered to the C(3) position of the cholic acid
component and a subpocket formed by amino acids Tyr366,
Tyr251, Val245, Phe243, Leu263, Phe273, and Leu367. Both 68
and 66 achieve further binding stabilization through π−π stacking
with Tyr366, and for 68, an additional H-bond with the hydroxyl
substituent of Tyr366 is predicted (Figure S4). In addition, the
second 4,7-ACQ ring is stabilized via H-bonding with Thr176.
Compound 68 is also stabilized through an H-bond with Ser259.
Furthermore, model analysis indicates proximity between the side
chain of Pro239 and the quinoline core of the C(24) 4,7-ACQ
component. The role of proline interactions with aromatic moieties
in the stabilization of small molecule binding has been reported53
(Figure S4).
Figure 2. Compounds 64 (orange carbons), 65 (purple carbons), and 67 (turquoise carbons) docked in the catalytic cleft of BoNT/A LC with key
amino acid residues emphasized in stick. Hydrogen bonding is shown for compound 64. The carbonyl oxygen from the acetoxy group at C(12)
(steroid numbering) coordinates the enzyme’s Zn2+ (not explicitly indicated). For full ligand interaction diagrams see Figure S6 in Supporting Information.
Figure 1. Compounds 52 (yellow carbons) and 54 (turquoise carbons) docked in the catalytic cleft of the BoNT/A LC with key amino acid residues
emphasized in stick. The carbonyl oxygen from the acetoxy group at the cholate C(7) (steroid numbering) coordinates the enzyme’s Zn2+ (not
explicitly indicated). For full ligand interaction diagrams see Figure S1 in Supporting Information. Hydrogen bonding is shown for compound 52.
The presence of a methyl group (cyan) on the C(24) nitrogen, 54, limits hydrogen bonding to only Glu55.
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β-C(3) derivatives are predicted to dock in the substrate
binding cleft in the opposite direction versus α-C(3) deriv-
atives. However, the β-C(3) derivatives retain the three major
binding points indicated above: i.e., coordination of the enzyme’s
catalytic Zn2+, a salt bridge with Glu164, and hydrophobic
stabilization of the 4,7-ACQ aromatic core are all observed. In
the β-C(3) series the coordination to Zn2+ is achieved via the
carbonyl oxygen of AcO-C(12) and the salt bridge with Glu164
is formed via the protonated amino group at C(3) (Figure 2; see
also Figure S6). Favorable hydrophobic interactions are observed
between the 4,7-ACQ core linked to C(24) and the pocket
composed of the same amino acid residues observed for α-C(3)
derivatives. Additional interactions in this area are π−π stacking
and H-bonding with Tyr366. New, stabilizing interactions include
H-bonds or salt bridges between C(24) ammonium groups and
Glu252 and Asp370. For 67 and 65, the second 4,7-ACQ
component engages in H-bonding with Asn174; this interaction
is possible because of a longer alkyl chain spacer compared to 64.
The carbonyl oxygen from the acetate at C(7) of compounds 67,
64, and 65 is positioned within interaction distance with the
backbone nitrogen atom of Ser259 (3.14 Å for 67, 2.90 Å for 64,
and 3.87 Å for 65), and because of the relative flexibility of the
binding site, it is feasible to assume that a hydrogen bond can be
formed (Figure 2). The docking scores for these three derivatives
followed the same trends as their Ki values (Table 4).
Examination of an overlap of the docked structures of the α-
C(3) series (66 and 68) and β-C(3) series (64, 65, and 67;
Figure S5, 3α-derivatives in pink shades, 3β-derivatives in green
shades) indicated that the latter is rotated 180° in the binding
site around the midpoint of the C(8)−C(9) bond. However,
the key functional groups of compounds in both series super-
imposed well. For example, superimpositions of the com-
pounds’ aliphatic aminos, aromatic aminos, quinolone cores,
and acetate groups that coordinate the enzyme’s Zn2+ ion are all
uniform. Hence, it appears that differences caused by alterations
in the stereochemistry at C(3) are compensated for by the
length of the alkyl spacers connecting the 4,7-ACQ fragments
and the central cholate components. Finally, the described over-
lap of the α- and β-series of bis-4,7-ACQ derivatives rationalizes
the good activities of diastereomer mixtures 62 and 63.
Antimalarial Activity. All synthesized compounds were
screened in vitro against three P. falciparum strains: D6 (CQ
susceptible (CQS) strain), W2 (CQ resistant (CQR) strain),
and TM91C235 (Thailand, a multidrug-resistant (MDR)
strain), following well-established protocols.54 In brief, the
malaria SYBR Green I based fluorescence (MSF) assay is a
microtiter plate drug sensitivity assay that uses the presence of
malarial DNA as a measure of parasitic proliferation in the
presence of antimalarial drugs or experimental compounds.
The intercalation of SYBR Green I dye, and its resulting fluores-
cence, is relative to parasite growth, and a compound that inhibits
the growth of the parasite will result in lower fluorescence.
The compounds’ antimalarial activities are shown in Table 3.
All of the compounds exhibited better IC90 activity against both
CQR strains in comparison to CQ, and nine are more potent
(IC90) against CQS strain D6 than CQ. When compared to
MFQ, seven compounds are more active against CQR strain
W2, and 19 are more active against MDR strain TM91C235
(IC90). In addition, three inhibitors are more active than
artemisinin (ART) against the W2 and TM91C235 strains: 56,
54, 16, and 56, 54, 42 and 16, respectively (IC90).
In general, ACQ2 derivatives are more active than ACQ3
derivatives, with an increase in the length of the alkyl chain
resulting in a further decrease in antimalarial activity (e.g., 14,
15 vs 12, 13, and the compounds may further lose activity via
the following set of transformations AcO−C(3)→ HO−C(3)→
OC(3)). In contrast to BoNT/A LC inhibitory activity,
further analysis of the compounds’ antimalarial activities did not
establish a unique pattern of substituent influence on potency.
Highly active (IC90 < 5 nM) and appreciably active (IC90
< 10 nM) compounds possess C(3)-amino, C(3)-OH, and
C(3)-N-Boc substituents on the steroidal core; the same holds
for the least active compounds (IC90 > 100 nM). However,
alkylation of the secondary aliphatic amino group at C(24)
(yielding a tertiary amine) favors antimalarial activity, as 56 and
54 are the most active derivatives. In general, the antimalarial
behavior of the new derivatives suggests that the contribution of
substituents to antimalarial activity is more complex than appears
at first glance. In this regard, the compounds will be submitted for
thorough analysis of their respective physicochemical parameters.
The resistance index (RI, Table 3) clearly indicates that most of
the compounds are more active against the CQS D6 strain than
against the CQ resistant strains. The above results clearly indicate
that the mode of action of the steroid-derived aminoquinolines is
similar to that of 9 (i.e., CQ), although the compounds are much
more active than the parent compound, as shown in Table 3.
This observation is supported by the results of a β-hematin
inhibition experiment. Specifically, derivative 23 was selected for
the evaluation of its ability to inhibit β-hematin formation using
a β-hematin inhibitory activity assay (BHIA). Subsequently, it
was found that 23 has an IC50 that is 3 times lower than that
of 9 (CQ) (i.e., 23 (IC50 = 0.399) vs 9 (IC50 = 1.09)), thereby
demonstrating a significantly better ability to interact with hematin
than 9.24 Hence, these results indicate that our present com-
pounds, like other ACQ-based antimalarials, most likely interfere
with the heme detoxification mechanism of malaria.
In general, the examined derivatives showed low metabolic
stability (Table 3). Out of the complete set of compounds, 57,
50, and 54 showed desirable in vitro stability, with t1/2 > 60 min
in both human liver microsomes (HLMs) and mouse liver micro-
somes (MLMs). Somewhat less stable were derivatives 57, 43,
and 17, which are stable against MLM but are moderately stable
(56) or insufficiently stable (43 and 17) against HLM.
The toxicity of the compounds was estimated using human
liver carcinoma cell line (HepG2) and peripheral blood mono-
nuclear cells (PBMC). In general, the HEPG2 assay for cytotoxicity
estimation revealed that almost all of the compounds are well
tolerated by this cell line, possessing IC50 ≥ 1000 nM. In addition,
high selectivity indices (SIs) were calculated for the most promising
antimalarials 54 and 56 (SI > 2300). In addition, 50, 42, 40, 22,
and 16 also displayed low toxicity (Table 3).
Of the tested compounds, the results indicate that 54 and 56
are the most prominent antimalarial agents. The only difference
between the two compounds is substitution at the C(3) amino
group: NH2 (54) and (CH3)2N (56). Derivative 56 showed
somewhat better in vitro activity against all examined malarial
strains (IC50, IC90); however, lower toxicity against HepG2 (54,
IC50 = 14 380 nM, SI = 5000−2326; 56, IC50 = 9212 nM, SI =
6823−3177) and better metabolic stability against HLM led to
the selection of 54 for in vivo testing.
Compound 54 was administrated po at 40 and 160 mg kg−1
day−1 on day 3, day 4, and day 5 after infection using the
Thompson test in ICR female mice with 107 × 1 parasites
infected with rodent P. berghei strain.24 Under both treatments
mice died on day 13 postinfection. All mice died of malaria, and
no signs of tissue damage caused by compound toxicity were
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observed upon necropsy. Unfortunately, this is one of many
situations when compound activity in a living organism does
not match excellent in vitro activity.
■ CONCLUSIONS
Second generation 4,7-ACQ-cholate-based inhibitors of the
BoNT/A LC that are significantly more potent than initially
discovered leads were described.42,43 The introduction of a
basic amino group at the C(3) position of the cholic acid com-
ponent markedly increased inhibitor potencies (IC50 = 0.81−
2.27 μM). The observation that the substrate binding cleft of
the BoNT/A LC is very flexible48 indicates that the enzyme can
conformationally adapt to accept large molecules.49 This led us
to evaluate two additional subclasses: bis(steroidal)-4,7ACQ
derivatives and bis(4,7-ACQ)cholic acid derivatives. The
bis(4,7-ACQ)cholic acid derivatives were found to possess Ki
values of <0.4 μM, and compound 67 was the most potent
derivative (inhibition (20 μM) of 95%, Ki = 0.103 μM).
Table 3. In Vitro Antimalarial Activities of Compounds Tested against P. falciparum Strains
W2a (nM) D6b (nM) TM91C235c (nM)
compd IC50 IC90 IC50 IC90 IC50 IC90 RI
d
HEPG2 IC50
(nM) SIe
PBMC IC50
(nM)
HLM/MLM
(min)f
12 11.38 32.50 16.87 34.21 27.74 77.92 2.28/0.95
13 9.42 18.98 9.72 13.80 14.54 31.85 2.31/1.38 980 104/101/67
14 23.92 46.52 54.49 2565 107/55/47
15 56.38 90.97 103.78 2643 47/29/25
16 6.58 10.70 2.91 5.13 6.71 13.26 2.58/2.08 2729 415/938/407 2814 7/30
17 12.76 18.79 9.30 16.46 11.92 30.27 1.84/1.14 1068 84/115/90 8/60
18 33.78 52.08 56.31 1585 47/30/28
19 33.85 36.56 40.63 2044 60/56/50
22 6.47 14.11 3.38 4.56 17.64 36.75 8.06/3.09 1929 299/571/109 52240 6/13
23 6.89 12.10 6.12 10.02 9.19 18.15 1.81/1.21 1111 161/182/121 2607 14/6
24 174.92 211.63 213.74 1230 7/6/6
25 42.09 47.53 51.60 1281 30/27/25
20 18.55 38.63 7.47 19.06 22.97 32.90 1.73/2.03 1809 98/242/79
21 11.77 16.88 6.91 10.47 22.26 47.33 4.52/1.61 1580 134/229/71
36 15.21 62.21 16.59 31.80 15.21 34.56 1.09/1.96 1922 126/116/126
37 26.40 35.84 12.75 36.50 28.12 39.85 1.09/0.98 1448 55/114/51
38 44.58 71.12 19.44 53.02 26.40 45.62 0.86/1.34 5854 131/301/222
39 34.44 96.36 37.51 74.71 30.29 56.22 0.75/1.29 4463 130/119/147 11/47
40 7.34 12.31 24.12 29.47 27.60 51.93 1.76/0.42 12797 1743/531/464
42 12.13 16.81 5.35 10.18 6.59 12.59 1.24/1.65 14480 1194/2707/2197 14/47
43 30.47 54.74 31.67 55.88 20.33 28.56 0.51/0.98 2828 93/89/139 11/60
44 8.05 11.69 8.93 10.94 16.34 22.63 2.07/1.07 2360 293/264/144
50 19.73 42.29 32.42 0.77/0.47g 14096 714/333/435 60/60
51 36.14 81.14 100.81 138.69 88.71 165.04 1.19/0.58 13823 382/137/156 7838
52 161.44 234.83 143.83 176.12 146.77 220.15 1.25/1.33 5610 35/39/38 7881
53 194.60 282.49 138.49 233.61 242.74 347.28 1.49/1.21 10419 54/75/43
54 2.88 3.74 3.60 4.46 6.18 9.20 2.06/0.84 14381 4993/3995/2327 2588 60/60
55 110.05 152.86 112.30 150.03 100.15 128.18 0.85/1.02 4972 45/44/50
56 1.35 1.35 2.35 2.63 2.90 3.32 1.26/0.51 9212 6824/3920/3176 2516 27/60
57 56.95 151.87 74.58 5278 93/35/71 60/60
60 78.0 105.17 86.77 113.93 85.89 175.28 1.54/0.92 1648 21/19/19
59 368.93 368.93 368.93 35417 96/96/96
61 217.77 413.75 244.96 321.27 297.19 312.51 0.97/1.29 2130 10/9/7
52 98.19 119.64 124.15 3771 38/32/30 302
63 108.31 143.32 194.74 4678 43/32/24
9 (CQ) 456.20 697.97 12.27 16.11 138.82 373.25 23.17/43.32
MFQ 4.93 15.25 15.70 39.09 36.50 134.07 3.43/0.39
ARTh 6.70 11.50 9.00 12.80 13.40 17.40 1.36/0.90
aP. falciparum Indochina W2 clone. bP. falciparum African D6 clone. cP. falciparum multidrug resistant TM91C235 strain (Thailand). dResistance
index (RI) is defined as the ratio of the IC90 for the resistant versus sensitive strain, TM91C235/D6 and W2/D6, respectively.
eSelectivity index (SI)
is defined as ratio of the IC50 for HepG2/W2, HepG2/D6, and HepG2/TM91C235, respectively.
fStability of compounds during incubation with
human (HLM) and mouse (MLM) liver microsomes. gFor this compound index is defined as the ratio of the IC50 for the resistant versus sensitive
strain, TM91C235/D6 and W2/D6, respectively; hAverage of greater than eight replicates.
Table 4. Ki Values and Docking Scores and of Bis-AQ
Derivatives
compd Ki (μM) docking score
a
64 0.300 ± 0.065 −14.481
65 0.389 ± 0.059 −13.809
66 0.285 ± 0.056 −12.932
67 0.103 ± 0.024 −16.471
68 0.300 ± 0.059 −13.224
aA lower score indicates better binding of a given ligand in the
substrate cleft.
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Compounds tested during BoNT/A challenge in primary
neurons were found to protect SNAP-25 by up to 89%. In
the presence of 5 μL of 100 nM solution of Baf, SNAP-25
protection was slightly higher; however, upon the addition of
25 μL of 100 nM solution of Baf, no further increase in
protection was observed. These results suggest that our
inhibitors can successfully protect SNAP-25 in the presence
of the BoNT/A holotoxin, with only slight additive effects
when given in combination with Baf. Docking simulations
rationalized the BoNT/A LC inhibitory activities of the
compounds in two main terms: (1) coordination of a carbonyl
acetate oxygen to Zn2+ and the expulsion of the catalytic water
and (2) formation of strong interactions between ligands and
catalytically important amino acid residues, including salt
bridges with Asp370 and Glu164 and π−π stacking/H-bonding
with Tyr366.
With respect to antimalarial activity, all of the compounds
exhibited better IC90 potencies against CQR strains versus CQ,
and nine compounds are more potent (IC90) against CQS
strain D6 than CQ. When compared to MFQ, seven com-
pounds are more active against CQR strain W2, and 19 are
more active against MDR strain TM91C235 (IC90). The two
most active compounds exhibit very high in vitro activity
against CQR strain W2 (1.35 nM and 3.74 nM, respectively); at
the same time both compounds are very active against the
BoNT/A LC (2.27 μM, 1.14 μM). However, it is disappointing
that compound 54, which possesses excellent in vitro anti-
malarial activity, failed to protect/cure mice when administered
at 40 and 160 mg kg−1 day−1 in a Thompson test.
■ EXPERIMENTAL SECTION
Chemistry. Melting points were determined on a Boetius PMHK
or a Mel-Temp apparatus and were not corrected. Optical rotations
were measured on a Rudolph Research Analytical automatic
polarimeter, Autopol IV, in dichloromethane (DCM) or methanol
(MeOH) as solvent. IR spectra were recorded on a Perkin-Elmer
spectrophotometer FT-IR 1725X. 1H and 13C NMR spectra were
recorded on a Varian Gemini-200 spectrometer (at 200 and 50 MHz,
respectively) and on a Bruker Ultrashield Advance III spectrometer
(at 500 and 125 MHz, respectively) employing indicated solvents
(vide infra) using TMS as the internal standard. Chemical shifts are
expressed in ppm (δ) values and coupling constants (J) in Hz. ESI
mass spectra were recorded on an Agilent Technologies 6210 time-of-
flight LC−MS instrument in positive ion mode with CH3CN/H2O
1/1 with 0.2% HCOOH as the carrying solvent solution. Samples were
dissolved in CH3CN or MeOH (HPLC grade purity). The selected
values were as follows: capillary voltage = 4 kV, gas temperature =
350 °C, drying gas = 12.l min−1, nebulizer pressure = 45 psig, frag-
mentator voltage = 70 V. The elemental analysis was performed on the
Vario EL III C,H,N,S/O elemental analyzer (Elementar Analysensys-
teme GmbH, Hanau, Germany). Thin-layer chromatography (TLC)
was performed on precoated Merck silica gel 60 F254 and RP-18 F254
plates. Column chromatography was performed on Lobar LichroPrep
Si 60 (40−63 μm) and RP-18 (40−63 μm) columns coupled to a
Waters RI 401 detector and on Biotage SP1system with UV detector
and FLASH 12+, FLASH 25+, or FLASH 40+ columns charged with
KP-SIL (40−63 μm, pore diameter 60 Å), KP-C18-HS (40−63 μm,
pore diameter 90 Å), or KP-NH (40−63 μm, pore diameter 100 Å) as
adsorbent. Compounds were analyzed for purity (HPLC) using a
Waters 1525 HPLC dual pump system equipped with an Alltech
Select degasser system, and dual λ 2487 UV−vis detector. For data
processing, Empower software was used (methods A and B).
Methods C and D involved use of Agylent Technologies 1260 liquid
chromatograph equipped with quaternary pump (G1311B), injector
(G1329B), 1260 ALS, TCC 1260 (G1316A), and detector 1260 DAD
VL+ (G1315C). For data processing, LC OpenLab CDS ChemStation
software was used. For details, see Supporting Information.
N1-(7-Chloroquinolin-4-yl)ethane-1,2-diamine (ACQ2), N1-(7-
chloroquinolin-4-yl)propane-1,3-diamine (ACQ3), N1-(7-chloroqui-
nolin-4-yl)butane-1,4-diamine (ACQ4), and N1-(7-chloroquinolin-4-yl)-
ethane-1,6-hexane (ACQ6) were prepared according to known
procedures.55
N-(3α,7α,12α-Triacetoxy-5β-cholan-24-yl)-N′-(7′-chloroquinolin-
4′-yl)ethane-1,2-diamine (12). Alcohol 11 (1.08g, 2.07 mmol) was
dissolved in DCM (100 mL). PCC (670 mg, 3.11 mmol) was added,
and the mixture was stirred at room temperature for 3.5 h. Reac-
tion mixture was filtered through a short column of SiO2 (eluent
DCM/EA = 7/3). Crude aldehyde was dissolved in DCM (150 mL).
ACQ2 (1.06 g, 4.78 mmol) was added, and mixture was stirred 15 min,
followed by addition of NaBH(OAc)3 (1.01 g, 4.76 mmol), and
stirring was continued at room temperature overnight. The mixture
was transferred into a separatory funnel. Water was added, and
following the intensive shaking, the water layer was adjusted to pH ≈
12 with 0.5 M NaOH solution. Water layer was extracted 2 times more
with DCM. Combined organic layers were rinsed with brine and dried
over anhydrous Na2SO4. Solvent was removed under reduced pressure
and crude mixture was prepared for column purification (dry flash,
SiO2, eluent EA, EA/MeOH gradient 95/5 → 9/1, EA/MeOH/NH3
gradient 18/0.1/0.1 → 18/0.7/0.7 and flash chromatography (Biotage
SP1 RP column, eluent MeOH/H2O gradient 8/2 → 9/1)]. Yield
793.4 mg (53%). Spectral and analytical data for compound 12 were
identical to the ones already described.43 HPLC purity, method A: tR =
8.583, area 95.04%. Method B: tR = 8.723, area 96.87%.
N-(3α-Hydroxy-7α,12α-diacetoxy-5β-cholan-24-yl)-N′-(7′-
chloroquinolin-4′-yl)ethane-1,2-diamine (16). Mixture of 12
(501 mg, 0.69 mmol) and anhydrous K2CO3 (169 mg, 1.22 mmol)
in dry MeOH (14 mL) was stirred at room temperature for 3 h and
poured onto ice/water mixture. Solid was filtered off and dried in
vacuum oven. Yield 460 mg (97%). Colorless foam softens at 118−
121 °C. [α]D
20 +0.040 (c 1.4 × 10−3 g/mL, DCM). IR (KBr): 3309w,
2930w, 2863w, 1715m, 1612w, 1580s, 1535w, 1449w, 1373m, 1332w,
1241s, 1138w, 1074m, 1019m, 967w, 937w, 897w, 878w, 850w, 805w,
767w cm−1. 1H NMR (500 MHz, CDCl3, δ): 8.51 (d, J = 5.1,
H-C(2′)), 7.94 (d, J = 1.8, H-C(8′)), 7.74 (d, J = 9.1, H-C(5′)), 7.36
(dd, J1 = 9.1, J2 =2.1, H-C(6′)), 6.38 (d, J = 5.4, H-C(3′)), 5.95 (bs, H-
N), 5.11−5.07 (m, H-C(12)), 4.92−4.88 (m, H-C(7)), 3.55−3.47 (m,
H-C(3)), 3.36−3,30 (m, 2H-C(9′)), 3.02 (t, J = 5.6, 2H-C(10′)),
2.67−2.57 (m, 2H-C(24)), 2.09 (s, CH3COO), 2.07 (s, CH3COO),
0.90 (s, CH3-C(10)), 0.82 (d, J = 6.5, CH3-C(20)), 0.71 (s, CH3-
C(13)). 13C NMR (125 MHz, CDCl3, δ): 170.61, 170.58, 151.97,
149.91, 149.03, 134.80, 128.58, 125.18, 121.34, 117.34, 99.12, 75.43,
71.56, 70.82, 49.75, 47.62, 47.48, 45.02, 43.39, 41.97, 41.01, 38.65,
37.74, 34.94, 34.84, 34.25, 33.28, 31.33, 30.49, 28.94, 27.29, 26.69,
25.55, 22.77, 22.52, 21.60, 21.40, 17.88, 12.20. (+)ESI-HRMS (m/z):
[M + 2H]2+ 341.7034 (error, −2.20 ppm), [M + H]+ 682.3980 (error,
−0.22 ppm). Combustion analysis (C39H56ClN3O5·H2O): calculated
C 66.88, H 8.35, N 6.00; found C 66.51, H 7.82, N 6.10. HPLC purity,
method A: tR = 8.651, area 96.19%. Method B: tR = 8.626, area 95.11%.
N-Methyl-N-(3α,7α,12α-triacetoxy-5β-cholan-24-yl)-N′-(7′-
chloroquinolin-4′-yl)ethane-1,2-diamine (20). Mixture of 12
(200 mg, 0.28 mmol), 37% formaldehyde (68.3 μL, 0.84 mmol),
NaBH(OAc)3 (237 mg, 1.12 mmol) in DCM (9 mL) was stirred at
room temperature until disappearance of starting compound (TLC,
SiO2, EA/MeOH/NH3 = 9:1:1). Reaction mixture was transferred into
separatory funnel. DCM (20 mL) and water (10 mL) were added. pH
of water layer was adjusted to pH 12 using 0.5 M NaOH, and the
mixture was worked up in the usual manner. Product was isolated after
column chromatography (dry flash, SiO2, gradient hexane/EA 4:6 →
EA). Yield 163 mg (80%). Colorless foam softens at 74−78 °C. [α]D20 +
0.089 (c 1.3 × 10−3 g/mL, DCM). IR (KBr): 3276w, 2947m, 2872w,
1732s, 1678s, 1614m, 1456w, 1379m, 1333w, 1251s, 1201s, 1134m,
1025w, 966w, 889w, 832w, 801w cm−1. 1H NMR (500 MHz, CDCl3, δ):
8.53 (d, J = 5.0, H-C(2′)), 7.96 (d, J = 2.0, H-C(8′)), 7.68 (d, J = 9.0,
H-C(5′)), 7.37 (dd, J1 = 2.0, J2 = 9.0, H-C(6′)), 6.37 (d, J = 5.5,
H-C(3′)), 6.08 (bs, H-N, exchangeable with D2O), 5.10 (s, H-C(12)),
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4.95−4.90 (m, H-C(7)), 4.61−4.54 (m, H-C(3)), 3.31−3.27 (m,
2H-C(9′)), 2.77−2.30, (m, 2H-C(10′)), 2.47−2.34 (m, 2H-C(24)),
2.28 (s, CH3-N), 2.08 (s, CH3COO), 2.07 (s, CH3COO), 2.05 (s,
CH3COO), 0.92 (s, CH3-C(10)), 0.83 (d, J = 6.6, CH3-C(20)), 0.72
(s, CH3-C(13)).
13C NMR (125 MHz, CDCl3, δ): 170.52, 170.47,
170.35, 152.05, 149.85, 149.01, 134.79, 125.13, 121.24, 117.35, 99.25,
75.41, 74.04, 70.67, 57.85, 55.15, 47.93, 45.08, 43.52, 41.26, 40.91,
39.60, 37.73, 35.24, 34.64, 34.59, 34.28, 33.59, 31.89, 31.21, 29.66,
28.95, 27.42, 26.85, 25.60, 24.15, 22.80, 22.54, 21.58, 21.47, 21.34,
17.98, 12.23. (+)ESI-HRMS (m/z): [M + H]+ 738.42320 (error,
−1.55 ppm). Combustion analysis for (C42H60ClN3O6·1.5H2O):
calculated C 65.91, H 8.30, N 5.49; found C 65.86, H 8.33, N 5.40.
HPLC purity, method B: tR = 8.703, area 96.21%. Method C: tR =
13.199, area 95.18%.
N-(3-Oxo-7α,12α-diacetoxy-5β-cholan-24-yl)-N′-(7′-chloro-
quinolin-4′-yl)ethane-1,2-diamine (22). Solution of 16 (460 mg,
0.64 mmol) and IBX56 (896 mg, 3.2 mmol) was dissolved in DMSO.
CF3CO2H (104.4 μL) was added, and the mixture was stirred at room
temperature. After 6 h mixture was poured onto water and pH was
adjusted to pH 11 using NaOH. The obtained solid was filtered off,
washed with H2O, and dried in vacuo. Crude product was purified
by column chromatography (dry flash, SiO2, eluent EA/MeOH
gradient 95/5 → 9/1, EA/MeOH/NH3 gradient 18/1/1 → 9/1/1)
and flash chromatography (Biotage SP1 RP column, eluent MeOH/
H2O gradient 8/2→ 9/1). Yield 367 (80%). Colorless foam softens at
75−78 °C. [α]D20 +0.069 (c 1.3 × 10−3 g/mL, DCM). IR (ATR):
2933w, 2861w, 2610w, 1714m, 1609w, 1578m, 1532w, 1443w, 1374w,
1330w, 1239s, 1169w, 1137w, 1073w, 1023w, 964w, 877w, 847w,
813w, 767w cm−1. 1H NMR (500 MHz, CDCl3, δ): 8.52 (d, J = 5.3,
H-C(2′)), 7.95 (d, J = 2.1, H-C(8′)), 7.71 (d, J = 8.9, H-C(5′)), 7.35
(dd, J1 = 8.9, J2 = 2.1, H-C(6′)), 6.38 (d, J = 5.5, H-C(3′)), 5.91 (bs,
H-N), 5.14 (bs, H-C(12)), 5.03−4.96 (m, H-C(7)), 3.37−3.29 (m,
2H-C(9′)), 3.06−2.94 (m, Hα-C(4) and 2H-C(10′), 2.68−2.57 (m,
2H-C(24)), 2.09 (s, CH3COO), 2.07 (s, CH3COO), 1.02 (s, CH3-
C(10)), 0.84 (d, J = 6.6, CH3-C(20)), 0.75 (s, CH3-C(13)).
13C NMR
(125 MHz, CDCl3, δ): 212.05, 170.37, 170.09, 152.02, 149.84, 149.07,
134.74, 128.66, 125.13, 121.24, 117.33, 99.15, 75.24, 70.55, 49.69,
47.67, 47.45, 45.05, 44.52, 43.22, 42.22, 42.10, 41.91, 37.71, 36.57,
36.08, 34.94, 34.35, 33.27, 30.87, 29.77, 27.24, 26.74, 25.79, 22.77,
21.59, 21.42, 21.28, 17.90, 12.22. (+)ESI-HRMS (m/z): [M + 2H]2+
340.6947 (error, −0.49 ppm), [M + H]+ 680.3812 (error, −1.86
ppm). Combustion analysis (C39H54ClN3O5): calculated C 68.85, H
8.00, N 6.18; found C 68.35, H 8.33, N 6.32. HPLC purity, method A:
tR = 8.484, area 95.76%. Method B: tR = 7.775, area 95.05%. Method
C: tR = 10.069, area 95.10%.
24-N-[(7-Chloroquinoline-4-yl)amino]ethylamino-3α-acet-
amido-7α,12α-diacetoxy-5β-cholane (36). Mixture of alcohol
33 (200 mg, 0.38 mmol) and PCC (123 mg, 0.57 mmol) in dry
DCM (40 mL) was stirred at room temperature for 3 h. Reaction
mixture was filtered through a short chromatography column.
Fractions that contained desired aldehyde were collected (dry flash,
SiO2, eluent DCM/EA = 7/3). To the stirred mixture (10 min) of
crude aldehyde obtained above, ACQ2 (193 mg, 0.874 mmol) in
DCM (20 mL) at room temperature NaBH(OAc)3 (185 mg, 0.874
mmol) was added, and stirring was continued at room temperature
for 6 h, followed by additional amount of NaBH(OAc)3 (2.75 mg,
13 mmol). After the reaction was completed Et3N was added, solvent
was removed under reduced pressure, and product was isolated after
column chromatography (dry flash, SiO2, EA, EA/MeOH gradient
95:5 → 9:1, EA/MeOH/NH3 = 18:0.1:0.1 → 18:0.7:0.7, Lobar
Lichroprep B RP MeOH/H2O = 9:1). Yield 112.7 mg (40%).
Colorless foam softness at 174−176 °C. [α]D20 +0.036 (c 1.0 × 10−3 g/mL,
DCM). IR (KBr): 3273m, 2950m, 2869m, 1716m, 1634m, 1614m,
1582s, 1539m, 1449m, 1377m, 1333w, 1250m, 1142w, 1024w, 969w,
817w, 729w, cm−1. 1H NMR (200 MHz, CDCl3, δ): 8.31 (d, J = 5.7,
H-C(2′)), 8.11 (d, J = 9.0, H-C(5′)), 7.77 (d, J = 1.7, H-C(8′)), 7.28
(dd, J1 = 1.6, J2 = 8.8, H-C(6′)), 6.29 (d, J = 5.7, H-C(3′)), 5.58 (d, J =
7.7, H-N), 5.06 (bs, H-C(12)), 4.89 (bs, H-C(7)), 3.60 (bs, H-C(3)
and 2H-C(9′)), 3.23 (bs, 2H-C(10′)), 2.83 (bs, 2H-C(24)), 2.08
(s, CH3COO), 2.07 (s, CH3COO), 1.96 (s, CH3CONH), 0.90 (bs,
CH3-C(10)), 0.80 (d, J = 6.2, CH3-C(20)), 0.69 (bs, CH3-C(13)).
13C
NMR (50 MHz, CDCl3, δ): 170.38, 170.24, 169.33, 151.12, 149.39,
146.17, 136.03, 125.81, 123.30, 116.80, 98.63, 75.43, 70.77, 49.65,
49.42, 47.52, 46.69, 45.01, 43.32, 41.39, 40.84, 37.62, 36.07, 35.36,
34.76, 34.21, 32.90, 31.25, 28.86, 28.04, 27.26, 25.51, 24.56, 23.53,
22.67, 21.63, 21.36, 17.72, 12.15. 1H NMR (500 MHz, CDCl3, δ): 8.27
(d, J = 5.5, H-C(2′)), 8.24 (d, J = 8.9, H-C(5′)), 7.81(s, H-C(8′)),
7.35−7.30 (m, H-C(6′)), 6.27 (d, J = 6.0, H-C(3′)), 5.37 (d, J = 7.8,
H-N), 5.07 (bs, H-C(12)), 4.90 (d, J = 2.3, H-C(7)), 3.90−3.40 (m,
H-N, exchangeable with D2O, H-C(3) and 2H-C(9′)), 3.33−3.23 (m,
2H-C(10′)), 2.93−2.80 (m, 2H-C(24)), 2.10 (s, CH3COO), 2.08 (s,
CH3COO), 1.97 (s, CH3CONH), 0.91 (bs, CH3-C(10)), 0.82 (d, J =
6.4, CH3-C(20)), 0.70 (bs, CH3-C(13)).
13C NMR (125 MHz,
CDCl3, δ): 170.38, 170.20, 169.24, 151.49, 148.68, 145.44, 136.43,
126.05, 125.19, 123.61, 116.66, 98.55, 75.43, 70.79, 49.66, 49.45,
47.54, 46.55, 45.05, 43.37, 41.43, 40.82, 37.67, 36.14, 35.42, 34.81,
34.26, 32.92, 31.28, 29.64, 28.90, 28.09, 27.30, 25.56, 24.32, 23.59,
22.73, 21.68, 21.41, 17.76, 12.21. (+)ESI-HRMS (m/z): [M + H]+
745.406 89 (error, −0.26 ppm). Combustion analysis (C41H59N4O5):
calculated C 68.07, H 8.22, N 7.75; found C 68.17, H 8.19, N 7.51.
HPLC purity, method A: tR = 2.088, area 98.43%. Method C: tR =
12.072, area 99.24%.
24-N-[(7-Chloroquinoline-4-yl)amino]ethylamino-3α-N′-tert-
butylcarbamate-7α,12α-diacetoxy-5β-cholane (40) and N,N-Di-
(3α-N″-tert-butylcarbamate-7α,12α-diacetoxy-5β-cholan-24-yl)-
N′-(7′-chloroquinoline-4′-yl)-1,3-ethanediamine (58). Com-
pounds 40 and 58 were obtained according to procedure described
for 36, using alcohol 35 as starting material (271 mg, 0.468 mmol).
Column chromatography (dry flash, SiO2, EA, EA/MeOH gradient
9:1→ 6:4, EA/MeOH/NH3 = 18:0.5:0.5→ 18:1.5:1.5, Lobar Lichroprep
RP column MeOH/H2O = 9:1). Yield 123 mg (34%) of 40 and
168 mg (26%) of 58.
40. Colorless foam softens at 112−116 °C. [α]D20 +0.057 (c 1.0 ×
10−3 g/mL, DCM). IR (KBr): 3343w, 2932m, 2866w, 1712s, 1610w,
1579s, 1527m, 1448m 1367s, 1330w, 1235s, 1167m, 1137m, 1062w,
1021m, 998m, 964w, 937w, 879w, 850w, 804w, 766w, 720w cm−1. 1H
NMR (500 MHz, CDCl3, δ): 8.51 (d, J = 5.1, H-C(2′)), 7.94 (d, J =
2.2, H-C(8′)), 7.72 (d, J = 8.8, H-C(5′)), 7.35 (dd, J1 = 9.0, J2 = 2.0,
H-C(6′)), 6.38 (d, J = 5.5, H-C(3′)), 5.95 (bs, N-H), 5.10−5.07 (m,
H-C(12)), 4.91−4.89 (m, H-C(7)), 3.35−3.32 (m, 2H-C(9′)), 3.28
(bs, H-C(3)), 3.03 (t, J = 5.7, 2H-C(10′)), 2.70−2.55 (m, 2H-C(24)),
2.10 (s, CH3COO), 2.06 (s, CH3COO), 1.44 (s, Boc-N), 0.91 (s,
CH3-C(10)), 0.82 (d, J = 6.2, CH3-C(20)), 0.71 (bs, CH3-C(13)).
13C
NMR (125 MHz, CDCl3, δ): 170.37, 170.25, 151.99, 149.88, 149.04,
134.80, 128.63, 125.18, 121.29, 117.34, 99.15, 75.45, 70.86, 65.81,
49.71, 47.67, 47.43, 45.03, 43.36, 41.89, 41.53, 37.71, 36.40, 35.48,
34.96, 34.24, 33.30, 31.29, 28.85, 28.40, 27.31, 26.67, 25.50, 22.80,
22.69, 21.61, 21.37, 17.91, 15.24, 12.20. (+)ESI-HRMS (m/z):
[M + H]+ 781.464 78 (error, −2.25 ppm). Combustion analysis for
(C44H65ClN4O6·H2O): calculated C 66.10, H 8.45, N 7.01; found C
65.93, H 8.60, N 6.12. HPLC purity, method A: tR = 2.085, area
99.22%. Method B: tR = 8.856, area 95.25%.
58. Colorless foam softens at 148−153 °C. [α]D20 +0.106 (c 1.1 ×
10−3 g/mL, DCM). IR (KBr): 3365w, 2934m, 2867w, 1712s, 1610w,
1580m, 1520mw, 1448w, 1366s, 1234s, 1166m, 1061w, 1021m, 998w,
965w, 938w, 880w, 851w, 804w, 721w cm−1. 1H NMR (500 MHz,
CDCl3, δ): 8.54 (d, J = 5.1, H-C(2′)), 7.97 (d, J = 1.9, H-C(8′)), 7.67
(d, J = 8.6, H-C(5′)), 7.35 (dd, J1 = 8.8, J2 = 1.8, H-C(6′)), 6.37 (d, J =
5.4, H-C(3′)), 6.11 (bs, N-H), 5.08 (bs, 2 × H-C(12)), 4.92−4.87 (m,
2 × H-C(7)), 3.27 (bs, 2H-C(9′) and 2 × H-C(3)), 2.88−2.76 (m,
2H-C(10′)), 2.53−2.40 (m, 2 × 2H-C(24)), 2.06 (s, 2 × CH3COO),
2.05 (s, 2 × CH3COO), 1.45 (s, 2 × Boc-N), 0.91 (s, 2 × CH3-
C(10)), 0.80 (d, J = 6.7, CH3-C(20)), 0.69 (bs, 2 × CH3-C(13)).
13C
NMR (125 MHz, CDCl3, δ): 170.34, 170.25, 155.10, 151.98, 149.82,
148.93, 134.83, 128.65, 125.16, 121.18, 117.35, 99.27, 79.20, 75.39,
70.83, 53.89, 51.76, 50.79, 47.94, 45.06, 43.37, 41.53, 39.70, 37.69,
36.39, 35.48, 35.18, 34.24, 33.56, 31.28, 28.85, 28.40, 27.34, 25.51,
23.90, 22.78, 22.69, 21.61, 21.30, 17.97, 12.22. (+)ESI-HRMS (m/z):
[M + 2H]2+ 670.929 92 (error, −0.94 ppm). Combustion analysis for
(C77H118ClN5O12·H2O): calculated C 68.04, H 8.90, N 5.15; found C
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67.84, H 9.05, N 5.02. HPLC purity, method C: tR = 11.618, area
99.15%. Method D: tR = 6.020, area 96.86%.
24-N-[(7-Chloroquinoline-4-yl)amino]propylamino-3α-N′-
tert-butylcarbamate-7α,12α-diacetoxy-5β-cholane (41) and
N,N-Di(3α-amino-tert-butylcarbamate-7α,12α-diacetoxy-5β-
cholan-24-yl)-N′-(7′-chloroquinoline-4′-yl)-1,3-propanedi-
amine (59). Procedure with NaBH4. Mixture of alcohol 35 (3.96 g,
6.84 mmol) and PCC (2.12 g, 9.86 mmol) in dry DCM (349 mL) was
stirred at room temperature for 3 h. Mixture was purified through a
short chromatography column. Fractions containing aldehyde were
collected (dry flash, SiO2, eluent DCM/EA = 7/3; TLC, SiO2,
EA/Hex = 1/1, visualization by CAM). The obtained crude aldehyde
was dissolved in dry MeOH (57 mL). ACQ3 (1.48 g 6.3 mmol) was
added, and resulting mixture was stirred at room temperature for 12 h.
NaBH4 (477 mg, 12.6 mmol) was added in one portion, and stirring
was continued for 1 h. The solvent was removed under reduced
pressure, and product was isolated upon column chromatography
[dry flash, SiO2, eluent Hex/EA gradient 1/1 → 2/8, EA, EA/MeOH
gradient 95/5 → 6/4, EA/MeOH/NH3 gradient 18/0.5/0.5 → 18/
2.1/2.1 and flash chromatography (Biotage SP1 RP column, eluent
MeOH/H2O gradient 7/3 → MeOH)].
41. Yield 2.24 g (41%). Colorless foam softness at 99−107 °C.
[α]D
20 +0.125 (c 1.4 × 10−3 g/mL, DCM). IR (KBr): 3313m, 2937m,
2868m, 1717s, 1613m, 1582s, 1536m, 1452m, 1372m, 1248s, 1211m,
1173m, 1137m, 1064w, 1024m, 985w, 848w, 852w, 803w, 768w, 608w
cm−1. 1H NMR (200 MHz, CDCl3, δ): 8.50 (d, J = 5.6, H-C(2′)),
7.93 (d, J = 2.2, H-C(8′), 7.87 (s, H-N-Boc, exchangeable with D2O),
7.74 (d, J = 9.0, H-C(5′), 7.34 (dd, J1 = 9.0, J2 = 2.2 H-C(6′)), 6.31 (d,
J = 5.6, H-C(3′)), 5.11 (bs, H-C(12)), 4.94/4.85 (m, H-C(7)), 4.39
(bs, H-N), 3.45−3.20 (m, 2H-C(9′) and H-C(3)), 3.00−2.85 (m, 2H-
C(11′)), 2.73/2.56 (m, 2H-C(24)), 2.11 (s, CH3COO), 2.03 (s,
CH3COO), 1.45 (s, (CH3)3C-N(Boc)), 0.91 (s, CH3-C(10)), 0.86 (d,
J = 6.2, CH3-C(20)), 0.74 (s, CH3-C(13)).
13C NMR (50 MHz,
CDCl3, δ): 170.49, 170.40, 155.20, 152.18, 150.57, 149.14, 134.53,
128.53, 124.65, 122.17, 117.60, 98.27, 79.22, 75.49, 70.79, 50.56,
49.65, 47.47, 45.01, 44.14, 43.50, 41.50, 37.65, 36.31, 35.45, 34.92,
34.20, 33.32, 31.23, 28.92, 28.39, 27.28, 27.19, 26.53, 25.53, 22.69,
21.54, 21.38, 17.90, 12.20. 1H NMR (500 MHz, CDCl3, δ): 8.49 (d,
J = 5.3, H-C(2′)), 7.93 (d, J = 2.1, H-C(8′), 7.83 (s, H-N-Boc,
exchangeable with D2O), 7.75 (d, J = 8.9, H-C(5′), 7.34 (dd, J1 = 8.8,
J2 = 1.9 H-C(6′)), 6.31 (d, J = 5.5, H-C(3′)), 5.10 (bs, H-C(12)),
4.93−4.86 (m, H-C(7)), 4.39 (bs, H-N), 3.40 (t, J = 5.7, 2H-C(9′)),
3.28 (bs, H-C(3)), 2.97−2.89 (m, 2H-C(11′)), 2.73−2.56 (m, 2H-
C(24)), 2.10 (s, CH3COO), 2.02 (s, CH3COO), 1.45 (s, (CH3)3C-
N(Boc)), 0.91 (s, CH3-C(10)), 0.85 (d, J = 6.4, CH3-C(20)), 0.73 (s,
CH3-C(13)).
13C NMR (125 MHz, CDCl3, δ): 170.42, 170.32,
151.94, 150.62, 148.93, 134.65, 128.35, 124.73, 122.20, 117.56, 98.26,
75.49, 70.82, 50.49, 49.46, 47.54, 45.06, 43.97, 43.50,41.55, 37.71,
36.36, 35.49, 34.97, 34.24, 33.35, 31.28, 28.94, 28.41, 27.32, 27.10,
26.44, 25.57, 22.78, 22.71, 21.56, 21.38, 17.93, 12.24. (+)ESI-HRMS
(m/z): [M + H]+ 795.4822 (error, +0.06 ppm). Combustion analysis
for (C45H67ClN4O6·0.5H2O): calculated C 67.18, H 8.52, N 6.96;
found C 67.01, H 8.42, N 6.74. HPLC purity, method A: tR = 1.952,
area 98.07%. Method C: tR = 15.915, area 98.61%.
Procedure with NaBH(OAc)3. Into stirred mixture of crude
aldehyde (3.80 g, 6,6 mmol) and ACQ3 (3.11 g, 13 mmol) in
DCM (126 mL) for 10 min at room temperature, NaBH(OAc)3
(2.8 mg, 13 mmol) was added. Stirring was continued for 12 h,
followed by additional amount of NaBH(OAc)3 (2.8 mg) and stirring
for 3 h. Then the solvent was removed under reduced pressure and
products were isolated upon column chromatography [dry flash (SiO2,
eluent EA, EA/MeOH gradient of 95/5 → 9/1, EA/MeOH/NH3
gradient of 18/0.5/0.5 → 9/1/1, and flash chromatography (Biotage
SP1, RP column, eluent MeOH/H2O gradient 75/25 → 95/5, N-H
column, eluent EA/Hex gradient 6/3→ EA). Yield 1.44 g of 41 (20%)
and 800 mg of bis-steroidal amine 59 (13%).
59. Colorless foam softens at 149−153 °C. [α]D20 +0.131 (c 1.6 ×
10−3 g/mL, DCM). IR (KBr): 3392m, 2950s, 2869m, 1735s, 1612m,
1581s, 1529m, 1450m, 1372s, 1244s, 1171s, 1065m, 1023m, 965m,
939w, 882w, 852w cm−1. 1H NMR (500 MHz, CDCl3, δ): 8.50 (d,
J = 5.4, H-C(2′)), 7.93 (d, J = 1.9, H-C(8′)), 7.75−7.65 (m, H-C(5′)
and H-N-Boc, exchangeable with D2O), 7.33 (dd, J1 = 8.8, J2 = 1.9, H-
C(6′)), 6.32 (d, J = 5.4, H-C(3′)), 5.05 (bs, 2 × H-C(12)), 4.88 (d, i =
2.2, 2 × H-C(7)), 4.45 (bs, H-N), 3.45−3.20 (m, 2H-C(9′) and 2 ×
H-C(3)), 2.72−2.58 (m, 2H-C(11′)), 2.54−2.40 (m, 2 × 2H-C(24)),
2.04 (s, 4 × CH3COO), 1.44 (s, 2 × (CH3)3C-N(Boc)), 0.90 (s, 2 ×
CH3-C(10)), 0.75 (d, J = 6.4, 2 × CH3-C(20)), 0.67 (s, 2 × CH3-
C(13)). 13C NMR (125 MHz, CDCl3, δ): 170.30, 170.24, 155.11,
152.06, 150.48, 149.08, 134.53, 128.47, 124.59, 121.98, 117.49, 98.41,
79.17, 75.36, 70.77, 54.98, 54.23, 50.71, 47.81, 44.98, 44.41, 43.31,
41.49, 37.63, 36.31, 35.44, 35.02, 35.18, 33.68, 31.23, 28.83, 28.36,
27.16, 25.47, 24.53, 23.59, 22.70, 22.64, 21.55, 21.26, 17.84, 12.15.
(+)ESI-HRMS (m/z): [M + H]+ 1354.8695 (error, −0.02 ppm).
Combustion analysis for C78H120ClN5O12: calculated C 69.13, H 8.92,
N 5.17; found C 69.05, H 8.84, N 5.37. HPLC purity, method C: tR =
11,964, area 97.93%. Method D: tR = 5.892, area 96.83%.
24-N-Methyl-N-[(7-chloroquinoline-4-yl)amino]ethylamino-
3α-methanesulfonamide-7α,12α-diacetoxy-5β-cholane (42).
Into stirred solution of 38 (121 mg, 0.16 mmol) and formaldehyde
(37%, 54 μL, 0.72 mmol) in 5 mL of DCM, NaBH(OAc)3 (203.3 g,
0.96 mmol) was added. When starting 38 was completely consumed
(TLC, SiO2, EA/MeOH/NH3 = 9:1:1), the reaction mixture was
suspended in DCM/H2O mixture, pH was adjusted to 12 with 0.5 M
NaOH, and transferred to separatory funnel and further worked-up in
usual manner. Product was isolated after column chromatography
(flash, Biotage SP1 NH column, eluent hexane/EA 4:6 → EA). Yield
103 mg (84%). Colorless foam softness at 110−114 °C. [α]D20 +0.048
(c 1.0 × 10−3 g/mL, DCM). IR (KBr): 3406m, 2949m, 2869m, 1731s,
1611w, 1582s, 1538w, 1452m, 1377m, 1320m, 1247s, 1150m, 1081w,
1023m, 969w, 880w, 849w, 812w, 763w, 733w cm−1. 1H NMR (500
MHz, CDCl3, δ): 8.54 (d, J = 5.5, H-C(2′)), 7.99 (d, J = 2.0, H-C(8′),
7.73 (d, J = 9.1, H-C(5′), 7.36 (dd, J1 = 8.9, J2 = 2.0 H-C(6′)), 6.37 (d,
J = 5.5, H-C(3′)), 6.29 (bs, H-N, exchangeable with D2O), 5.09 (bs,
H-C(12)), 4.95−4.90 (m, H-C(7)), 4.60−4.37 (m, H-N, exchangeable
with D2O), 3.34 (bs, 2H-C(9′)), 3.20−3.10 (m, H-C(3)), 2.96 (s,
CH3-N), 2.80 (t, J = 5.8, 2H-C(10′)), 2.52−2.40 (m, 2H-C(24)), 2.32
(s, CH3-SO2N), 2.07 (s, 2× CH3COO), 0.92 (s, CH3-C(10)), 0.82 (d,
J = 6.6, CH3-C(20)), 0.71 (s, CH3-C(13)).
13C NMR (125 MHz,
CDCl3, δ): 175.77, 170.41, 170.24, 151.41, 150.17, 148.33, 135.13,
127.96, 125.31, 121.49, 117.23, 99.02, 75.36, 70.66, 57.70, 54.89,
54.02, 47.84, 45.06, 43.38, 41.92, 41.61, 41.22, 39.53, 37.69, 37.36,
35.43, 35.16, 34.07, 33.44, 31.19, 29.40, 28.86, 27.37, 25.49, 23.64,
22.78, 22.61, 22.14, 21.57, 21.30, 17.94, 12.21. (+)ESI-HRMS (m/z):
[M + H]+ 773.407 72 (error, +0.53 ppm). Combustion analysis for
(C41H61ClN4O6S·2H2O): calculated C 60.83, H 8.09, N 6.92, S 3.96;
found C 60.55, H 7.92, N 6.81, S 4.00. HPLC purity, method A: tR =
1.868, area 99.31%. Method B: tR = 1.859, area 98.31%.
24-N-Methyl-N-[(7-chloroquinoline-4-yl)amino]ethylamino-
3α-N′-tert-butylcarbamate-7α,12α-diacetoxy-5β-cholane (44).
Into a stirred solution of 40 (1.00 g, 1.28 mmol) and formaldehyde
(37%, 190 μL, 2.55 mmol) in dry MeOH (30 mL) was added a
suspension of NaBH3CN (81 mg, 1.28 mmol) and anhydrous ZnCl2
(88 mg, 0.64 mmol) in MeOH (10 mL). After 2 h of stirring at room
temperature the additional amount of NaBH3CN (41 mg, 0.64 mmol)
and anhydrous ZnCl2 (44 mg, 0.32 mmol) were added as MeOH
(10 mL) suspension and stirring was continued for 1 h. Solvent was
evaporated under reduced pressure, and remaining residue was
transferred into a separatory funnel as DCM suspension. Water was
added and pH was adjusted to pH 12 with 0.5 M NaOH, and the
organic layer was worked up in the usual manner. Product was
obtained after flash column chromatography (Biotage SP NH column,
eluent hexane/EA 4:6 → 2:6). Yield 968.4 mg (95%). Colorless foam
softens at 96−101 °C. [α]D20 +0.163 (c 2.0 × 10−3 g/mL, DCM). IR
(ATR): 3376w, 2949m, 2868w, 2802w, 1731s, 1611w, 1581s, 1528m,
1452m, 1374s, 1331w, 1246s, 1171m, 1063w, 1023m, 965w, 940w,
881w, 850w, 807w, cm−1. 1H NMR (500 MHz, CDCl3, δ): 8.46 (d, J =
5.4, H-C(2′)), 7.89 (s, J = 2.0, H-C(8′)), 7.71 (d, J = 8.9, H-C(5′)),
7.30 (dd, J1 = 8.8, J2 = 2.1, H-C(6′)), 6.33 (d, J = 5.4, H-C(3′)), 6.07
(s, H-N-Boc, exchangeable with D2O), 5.06 (s, H-C(12)), 4.92−4.88
(m, H-C(7)), 4.42 (bs, H-C(3)), 3.45 (s, CH3-N), 3.33 (bs, 2H-C(9′)),
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3.05−2.95 (m, 2H-C(11′)), 2.70−2.43 (m, 2H-C(24) and H-N,
exchangeable with D2O), 2.07 (s, CH3COO), 2.04 (s, CH3COO),
1.42 (s, (CH3)3C-N(Boc)), 0.88 (s, CH3-C(10)), 0.79 (d, J = 6.6,
CH3-C(20)), 0.68 (s, CH3-C(13)).
13C NMR (125 MHz, CDCl3, δ):
170.34, 170.27, 151.80, 149.92, 148.87, 134.77, 128.36, 125.11, 121.43,
117.29, 99.98, 75.41, 70.82, 50.43, 49.66, 47.60, 47.33, 44.97, 43.30,
41.83, 41.48, 37.65, 36.35, 35.44, 34.89, 34.19, 33.23, 31.24, 28.79,
28.35, 27.25, 26.45, 25.45, 22.74, 22.63, 21.57, 21.31, 17.85, 12.15.
(+)ESI-HRMS (m/z): [M + H]+ 795.481 85 (error, −0.43 ppm).
Combustion analysis for C45H67ClN4O6: calculated C 67.94, H 8.49, N
7.04; found C 67.72, H 8.63, N 6.75. HPLC purity, method A: tR =
1.994, area 99.12%. Method C: tR = 9.936, area 98.20%.
24-N-[(7-Chloroquinoline-4-yl)amino]ethylamino-3α-N′,N′-
dimethylamino-7α,12α-diacetoxy-5β-cholane (50). Into a stirred
mixture of crude 48 (817 mg, 0.90 mmol) and formaldehyde (37%,
0.2 mL, 2.8 mmol) in dry methanol (8 mL) at room temperature was
added a suspension of anhydrous ZnCl2 (61 mg, 0.45 mmol) and
NaBH3CN (56.8 mg, 0.90 mmol) in dry methanol (8 mL). The
reaction mixture was stirred for 24 h, and the solvent was removed
under reduced pressure. The residue was transferred into a separatory
funnel as DCM solution, and water was added. pH was adjusted to pH
12 with 0.1 M NaOH. Layers were separated. Water layer was
extracted with DCM (2 × 15 mL), and combined organic layers were
washed with saturated NaHCO3 and brine and dried over anhydrous
Na2SO4. Solution was filtered off. The solvent was removed under
reduced pressure, and crude product (625 mg) was dissolved in
solution of piperidine in DCM (20%, 27 mL). Reaction mixture was
stirred for a further 24 h at room temperature, and the solvent was
removed under reduced pressure, transferred into a separatory funnel
as DCM solution, and worked up in the usual manner. The product
was isolated after column chromatography purification [dry flash, SiO2,
eluent MeOH, MeOH/NH3 gradient 95/5 → 9/1 and flash
chromatography (Biotage SP1, eluent EA/Hex, gradient 6/4 → EA,
gradient EA/MeOH 95/5 → 9/1)]. Yield 268 mg (55%). Colorless
foam softens at 78−82 °C. [α]D20 +0.056 (c 1.8 × 10−3 g/mL, DCM).
IR (KBr): 331w, 2935s, 2866m, 2772w, 1730s, 1610w, 1580s, 1534w,
1449m, 1375m, 1330w, 1242s, 1140w, 1069w, 1024w, 966w, 877w,
808w cm−1. 1H NMR (200 MHz, CDCl3, δ): 8.52 (d, J = 5.1,
H−C(2′)), 7.94 (d, J = 2.2, H-C(8′)), 7.73 (d, J = 9.0, H-C(5′)), 7.35
(dd, J1 = 9.0, J2 = 2.2, H-C(6′)), 6.39 (d, J = 5.6, H-C(3′)), 5.94 (bs,
H-N, exchangeable with D2O), 5.08 (bs, H-C(12)), 4.90−4.70 (m, H-
C(7)), 3.40−3.26 (m, 2H-C(9′)), 3.08−2.96 (m, 2H-C(11′)), 2.70−
2.54 (m, 2H-C(24)), 2.27 (s, (CH3)2N), 2.10 (s, CH3COO), 2.07 (s,
CH3COO), 0,90 (s, CH3-C(10)), 0.82 (d, J = 6.2, CH3-C(20)), 0.71
(s, CH3-C(13)).
13C NMR (50 MHz, CDCl3, δ): 170.68, 170.58,
152.05, 149.86, 134.74, 128.63, 125.12, 121.28, 117.31, 99.12, 75.49,
70.94, 64.98, 49.71, 47.56, 47.43, 44.96, 43.30, 42.19, 41.90, 41.68,
37.64, 35.67, 34.89, 34.32, 33.23, 32.74, 31.50, 28.86, 27.24, 26.66,
25.40, 24.05, 22.67, 21.60, 21.40, 17.81, 12.13. (+)ESI-HRMS (m/z):
[M + H]+ 709.446 54 (error, +1.59 ppm). Combustion analysis for
C41H61ClN4O4·2H2O: calculated C 66.06, H 8.79, N 7.52; found C
66.22, H 8.98, N 7.38. HPLC purity, method A: tR = 1.925, area
98.15%. Method B: tR = 7.942, area 96.45%.
24-N-[(7-Chloroquinoline-4-yl)amino]ethylamino-3α-amino-
7α,12α-diacetoxy-5β-cholane (52). Compound 40 (100 mg,
0.128 mmol) was stirred at room temperature in DCM/TFA mixture
(2 mL, 1:1, v/v) for 3 h. Solvent was removed under reduced pressure,
and the residue was transferred as DCM solution to separatory funnel
and worked up in the usual manner. Yield 83 mg (95.3%). Colorless
foam softens at 94−97 °C. [α]D20 +0.046 (c 1.1 × 10−3 g/mL, DCM).
IR (ATR): 3286w, 2932m, 2860m, 1724s, 1610w, 1578s, 1533w,
1448m, 1374m, 1330w, 1238s, 1135w, 1077w, 1021m, 964w, 936w,
878w, 847w, 806w, 766w cm−1. 1H NMR (500 MHz, CDCl3, δ): 8.51
(d, J = 5.4, H-C(2′)), 7.94 (d, J = 2.0, H-C(8′)), 7.72 (d, J = 8.7, H-
C(5′)), 7.35 (dd, J1 = 8.9, J2 = 2.2, H-C(6′)), 6.37 (d, J = 5.4,
H-C(3′)), 5.95 (bs, H-N,), 5.08 (bs, H-C(12)), 4.92−4.86 (m, H-
C(7)), 3.37−3.30 (m, 2H-C(9′)), 3.03 (t, J = 5.7, 2H-C(11′)), 2.68−
2.56 (m, 2H-C(24) and H-C(3)), 2.10 (s, CH3COO), 2.07 (s,
CH3COO), 0.90 (s, CH3-C(10)), 0.82 (d, J = 6.4, CH3-C(20)), 0.71
(s, CH3-C(13)).
13C NMR (125 MHz, CDCl3, δ): 170.64, 170.60,
151.98, 149.88, 149.01, 134.80, 128.59, 125.17, 121.31, 117.33, 99.13,
75.49, 70.89, 51.64, 49.72, 47.62, 47.43, 45.03, 43.39, 41.89, 41.49,
39.41, 37.76, 35.50, 34.94, 34.36, 33.28, 31.42, 31.16, 28.98, 27.29,
26.64, 25.58, 22.78, 21.64, 21.46, 17.87, 12.19. (+)ESI-HRMS (m/z):
[M + 2H]2+ 341.210 68 (error, −0.04 ppm). Combustion analysis for
C39H57ClN4O4·H2O: calculated C 66.98, H 8.50, N 8.01; found C
66.84, H 8.32, N 7.92. HPLC purity, method A: tR = 2.004, area
98.23%. Method B: tR = 7.973, area 95.08%.
24-N-Methyl-N-[(7-chloroquinoline-4-yl)amino]ethylamino-
3α-amino-7α,12α-diacetoxy-5β-cholane (54). Compound 44
(800 mg, 1.0 mmol) was stirred at room temperature in DCM/TFA
mixture (16 mL, 1:1, v/v) for 1.5 h. Then the solvent was removed
under reduced pressure, and the residue was transferred as DCM
solution into a separatory funnel and worked up in the usual manner.
Product was isolated after flash column chromatography (Biotage SP,
SiO2, eluent EA/MeOH, gradient 9:1→ 55/45). Yield 245 mg (35%).
Colorless foam softens at 62−64 °C. [α]D20 +0.080 (c 2.0 × 10−3 g/mL,
DCM). IR (ATR): 3409m, 2947s, 2865m, 1729m, 1668w, 1612w,
1582s, 1536w, 1451m, 1378m, 1331w, 1244s, 1157w, 1136w, 1077w,
1024m, 964w, 879w, 848w, 807w cm−1. 1H NMR (500 MHz, CDCl3, δ):
8.49 (d, J = 5.3, H-C(2′)), 7.92 (d, J = 2.0, H-C(8′)), 7.65 (d, J =
8.9, H-C(5′)), 7.31 (dd, J1 = 8.9, J2 = 2.1, H-C(6′)), 6.33 (d, J = 5.3,
H-C(3′)), 6.02−6.96 (m, H-N, exchangeable with D2O), 5.08−5.03
(m, H-C(12)), 4.86 (d, J = 2.7, H-C(7)), 3.24 (q, J = 5.5, 2H-C(9′)),
2.70 (d, J = 5.9, 2H-C(11′)), 2.60−2.52 (m, H-C(3)), 2.43−2.30 (m,
2H-C(24)), 2.23 (s, CH3-N), 2.05 (s, 2 × CH3COO), 0.87 (s, CH3-
C(10)), 0.79 (d, J = 6.6, CH3-C(20)), 0.68 (s, CH3-C(13)).
13C NMR
(125 MHz, CDCl3, δ): 170.56, 152.05, 149.73, 149.04, 134.64, 128.64,
125.00, 121.19, 117.29, 99.18, 75.43, 70.84, 57.80, 55.11, 51.59, 47.78,
45.02, 43.38, 41.46, 41.25, 39.57, 39.49, 37.71, 35.49, 35.13, 34.29,
33.46, 31.36, 31.23, 28.94, 27.33, 25.54, 24.04, 22.73, 21.59, 21.37,
17.90, 12.15. (+)ESI-HRMS (m/z): [M + H]+ 695.429 22 (error,
−0.78 ppm). Combustion analysis for C40H59ClN4O4·H2O: calculated
C 67.34, H 8.62, N 7.85; found C 66.98, H 8.73, N 7.62. HPLC purity,
method A: tR = 1.905, area 99.44%. Method C: tR = 11.413, area
96.83%.
24-N-Methyl-N-[(7-chloroquinoline-4-yl)amino]ethylamino-
3α-N′,N′-dimethylamino-7α,12α-diacetoxy-5β-cholane (56).
Into a stirred solution of 54 (190 mg, 0.27 mmol) and formaldehyde
(37%, 50 μL, 0.67 mmol) in dry MeOH (2 mL) was added a
suspension of NaBH3CN (13 mg, 0.21 mmol) and anhydrous ZnCl2
(29 mg, 0.21 mmol) in dry MeOH (2 mL). After the reaction
was completed (TLC, SiO2, EA/NH3/MeOH = 9:1:1) the solvent was
evaporated under reduced pressure. The obtained residue was
transferred into a separatory funnel as DCM suspension. Water
was added. The pH was adjusted to pH 12 with 0.5 M NaOH, and the
reaction was further worked up in the usual manner. Product was
obtained after column chromatography (dry flash, SiO2, eluent EA,
EA/MeOH gradient 9:1 → 8/2, EA/NH3/MeOH = 18:0.5:0.5 →
18:1.5:1.5). Yield 82 mg (42%). Colorless foam softens at 75−80 °C.
[α]D
20 +0.023 (c 2.0 × 10−3 g/mL, DCM). IR (ATR): 3424s, 2929s,
2867m, 1731s, 1612w, 1582s, 1531w, 1452m, 1377m, 1330w, 1244s,
1163w, 1070w, 1026m, 966w, 879w, 807w cm−1. 1H NMR (500 MHz,
CDCl3, δ): 8.53 (d, J = 5.4, H-C(2′)), 7.95 (d, J = 2.0, H-C(8′)), 7.68
(d, J = 9.0, H-C(5′)), 7.35 (dd, J1 = 8.9, J2 = 2.1, H-C(6′)), 6.37 (d, J =
5.4, H-C(3′)), 6.00 (bs, H-N, exchangeable with D2O), 5.11−5.07 (m,
H-C(12)), 4.92−4.87 (m, H-C(7)), 3.31−3.26 (m, 2H-C(9′)), 2.74 (t,
J = 5.8, 2H-C(11′)), 2.46−2.35 (m, 2H-C(24)), 2.27 (s, (CH3)2N-
C(3)), 2.26 (s, CH3-N), 2.08 (s, CH3COO), 2.07 (s, CH3COO), 0.91
(s, CH3-C(10)), 0.83 (d, J = 6.6, CH3-C(20)), 0.72 (s, CH3-C(13)).
13C NMR (125 MHz, CDCl3, δ): 170.64, 170.59, 152.15, 149.81,
149.14, 134.75, 128.78, 125.10, 121.22, 117.38, 99.28, 75.54, 70.99,
65.02, 57.86, 55.20, 47.80, 45.10, 43.43, 42.10, 41.81, 41.30, 39.62,
37.77, 35.77, 35.27, 34.44, 33.56, 32.61, 31.59, 28.96, 27.43, 25.50,
24.15, 23.93, 22.82, 22.76, 21.65, 21.40, 17.98, 12.23. (+)ESI-HRMS
(m/z): [M + H]+ 723.460 48 (error, −0.80 ppm). Combustion
analysis for C42H63ClN4O4: calculated C 69.73, H 8.78, N 7.74; found
C 69.52, H 8.60, N 7.63. HPLC purity, method A: tR = 1.849, area
98.82%. Method D: tR = 5.179, area 98.67%.
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N,N-Di(3α-amino-7α,12α-diacetoxy-5β-cholan-24-yl)-N′-(7′-
chloroquinoline-4′-yl)-1,3-ethanediamine (60). Compound 58
(140 mg, 0.104 mmol) was stirred at room temperature in DCM/TFA
mixture (2 mL, 1:1, v/v) for 3 h. Solvent was removed under reduced
pressure, and the residue was dissolved in DCM containing 5% MeOH
and transferred into a separatory funnel. The organic layer was washed
twice with saturated Na2CO3, once with brine, and dried over
anhydrous Na2SO4. Solution was filtered off, and the solvent was
removed under reduced pressure. Yield 75.7 mg (64%). Colorless
foam softens at 128−132 °C. [α]D20 +0.032 (c 1.2 × 10−3 g/mL,
DCM). IR (KBr): 2936m, 2864m, 1726s, 1611w, 1580m, 1526w,
1446w, 1375s, 1331w, 1238s, 1199.6m, 1132m, 1076w, 1021s, 964w,
937w, 878w, 832w, 801w, 765w, 720w cm−1. 1H NMR (500 MHz,
CDCl3, δ): 8.53 (d, J = 5.3, H-C(2′)), 7.96 (d, J = 2.1, H-C(8′)), 7.64
(d, J = 9.2, H-C(5′) 7.35 (dd, J1 = 8.9, J2 = 2.1, H-C(6′)), 6.37 (d, J =
5.3, H-C(3′)), 6.03−5.99 (m, H-N, exchangeable with D2O), 5.07 (bs,
2 × H-C(12)), 4.91−4.86 (m, 2 × H-C(7)), 3.29−3.21 (m, 2H-C(9′)
and 2 × H2N), 2.84−2.76 (m, 2H-C(11′)), 2.64−2.55 (m, 2 × H-
C(3)), 2.51−2.37 (m, 2 × 2H-C(24)), 2.07 (s, 2 × CH3COO), 2.06 (s,
2 × CH3COO), 0.90 (s, 2 × CH3-C(10)), 0.80 (d, J = 6.6, 2 × CH3-
C(20)), 0.69 (s, 2 × CH3-C(13)).
13C NMR (125 MHz, CDCl3, δ):
170.60, 152.16, 149.74, 149.13, 134.72, 128.81, 125.09, 121.06, 117.37,
99.33, 75.45, 70.90, 53.85, 51.74, 51.65, 47.93, 45.07, 43.39, 41.51, 39.73,
39.53, 35.17, 34.36, 33.58, 31.42, 31.28, 28.99, 27.33, 25.59, 23.97, 22.79,
21.65, 21.41, 17.95, 12.21. (+)ESI-HRMS (m/z): [M + 2H]2+ 570.878
12 (error, −1.85 ppm) [M + H]+ 1140.748 97 (error, −2.51 ppm).
Combustion analysis for C67H102ClN5O8·H2O: calculated C 69.43, H
9.04, N 6.04; found C 69.39, H 9.27, N 5.91. HPLC purity, method A:
tR = 1.838, area 97.10%. Method D: tR = 5.321, area 96.33%.
N,N′-Bis{2-[(7-chloroquinoline-4-yl)amino]ethyl}-7α,12α-diace-
toxy-5β-cholane-3,24-diamine (62, Mixture of Diastereoisomers).
Mixture of 22 (385 mg, 0.57 mmol) and ACQ2 (251 mg, 1.13 mmol)
in dry MeOH (9 mL) was stirred at room temperature for 12 h. Then
NaBH3CN (45 mg, 0.72 mmol) was added in one portion, and after
1 h of stirring at room temperature glacial AcOH (3 drops) was added.
Reaction mixture was stirred for further 48 h at room temperature.
The reaction was quenched with Et3N (3 drops). Solvent was removed
under reduced pressure, and product was isolated by column
chromatography (dry flash, SiO2, eluent EA, EA/MeOH gradient
95/5 → 1/9, EA/MeOH/NH3 gradient 18/1/1 → 9/1/1, flash,
Biotage SP1, RP column, eluent gradient MeOH/H2O 8/2 → 9/1).
Yield 299 mg (59%). Colorless foam softens at 108−113 °C. [α]D20
+0.070 (c 1.4 × 10−3 g/mL, DCM). IR (ATR): 3379w, 2929m, 2863w,
1722m, 1611w, 1581s, 1535w, 1450w, 1375m, 1330w, 1248m, 1170w,
1137w, 1078w, 1024w, 965w, 879w, 849w, 807w cm−1. 1H NMR (200
MHz, CDCl3, δ): 8.50 (d, J = 5.6, 2 × H-C(2′)), 7.94 (d, J = 1.7, 2 ×
H-C(8′)), 7.78−7.68 (m, 2 × H-C(5′)), 7.37−7.26 (m, 2 × H-C(6′)),
6.42−6.32 (m, 2 × H-C(3′)), 6.11−5.89 (m, 2 × H-N exchangeable
with D2O), 5.11(bs, H-C(12)), 4.90 (bs, H-C(7)), 3.33 (bs, 2 × 2H-
C(9′)), 3.08−2.92 (m, 2 × 2H-C(10′) and H-C(3)), 2.70−2.55 (m,
2H-C(24)), 2.10 (s, CH3COO), 2.08 (s, CH3COO), 0.96 (s, CH3-
C(10)), 0.83 (d, J = 6.2, CH3-C(20)), 0.72 (s, CH3-C(13)).
13C NMR
(50 MHz, CDCl3, δ): 170.60, 170.51, 170.44, 151.96, 149.92, 148.97,
134.77, 128.56, 128.49, 125.18, 125.14, 121.39, 121.22, 121.13, 117.31,
99.16, 99.09, 75.51, 71.01, 70.90, 57.83, 52.04, 49.71, 47.60, 47.43,
44.96, 44.79, 43.30, 42.72, 42.32, 41.92, 41.44, 37.65, 36.96, 36.13,
35.34, 34.87, 34.71, 33.47, 33.25, 31.37, 31.10, 29.99, 28.93, 28.44,
28.26, 27.26, 26.62, 25.62, 24.87, 23.22, 22.74, 21.56, 21.29, 17.83,
12.13. 1H NMR (500 MHz, CDCl3, δ): 8.50 (d, J = 5.3, 2 × H-C(2′)),
7.97−7.91 (m, 2 × H-C(8′)), 7.76−7.64 (m, 2 × H-C(5′)), 7.37−7.30
(m, 2 × H-C(6′)), 6.41−6.34 (m, 2 × H-C(3′)), 6.07−5.84 (m, 2 ×
H-N exchangeable with D2O), 5.14−5.04 (m, H-C(12)), 4.93−4.86
(m, H-C(7)), 3.39−3.25 (m, 2 × 2H-C(9′)), 3.07−2.9 (m, 2 ×
2H-C(10′)) 2.68−2.56 (m, H-C(3)), 2.26−2.13 (m, 2H-C(24)), 2.09
(s, CH3COO), 2.07 (s, CH3COO), 2.01 (s, CH3COO), 0.96 (s,
CH3-C(10)), 0.92 (s, CH3-C(10)), 0.85−0.79 (m, CH3-C(20)), 0.72
(s, CH3-C(13)), 0.71 (s, CH3-C(13)).
13C NMR (125 MHz, CDCl3,
δ): 170.44, 151.96, 149.91, 149.01, 134.79, 128.61, 128.55, 125.19,
125.16, 121.34, 121.09, 117.34, 99.18, 99.11, 75.54, 71.05, 57.87,
52.11, 49.71, 47.67, 47.47, 45.02, 44.87, 43.35, 42.75, 42.39, 41.96,
41.52, 37.73, 36.19, 34.93, 34.76, 33.54, 33.31, 31.16, 30.06, 28.99,
28.33, 27.31, 26.70, 25.67, 25.53, 24.95, 23.25, 22.79, 21.58, 21.31,
17.91, 12.19. (+)ESI-HRMS (m/z): [M + 2H]2+ 443.2334 (error,
+0.03 ppm) [M + H]+ 885.4587 (error, +0.96 ppm). Combustion
analysis (C50H66Cl2N6O4·1.5 H2O): calculated C 65.77, H 7.62, N
9.20; found C 65.30, H 7.24, N 9.07. HPLC purity, method B: tR =
1.788, area 98.83%. Method C: tR1 = 10.371, tR2 = 10 566, area 95.15%.
Method D: tR1 = 4.947, tR2 = 5.036, area 96.07%.
Molecular Modeling. The structure of BoNT/A LC and binding
site (BS) used in this study was obtained from previously published
crystal structure of protein (PDB code 3DS9).52 All ligand structures
were built in Maestro (Maestro, version 9.3; Schrödinger, LLC: New
York, NY, 2012), and their structures were optimized in Semiempirical
NNDO module of Schrödinger Suite 2012 (Schrod̈inger Suite 2012
Semiempirical NDDO Module; Schrödinger LLC: New York, NY, 2012),
using the RM1 method. Ionization states for all ligands were examined
using sequential pKa estimation in the Epik module (Epik, version 2.3;
Schrödinger, LLC: New York, NY, 2012). Ligand log P were calculated
using QikProp module (QikProp, version 3.5; Schrödinger, LLC: New
York, NY, 2012). Grid docking of the ligands were performed using
Glide ligand docking (Glide, version 5.8; Schrödinger, LLC: New York,
NY, 2012), using standard precision and flexible ligand sampling,
without any additional constraints. Generated docking structures were
refined and used for the next step. All structures were docked in
ionization state proposed by results of Epik pKa prediction for pH 7.0 ±
2.0, with protonated aliphatic nitrogen atoms in structure. For the next
step, Induced Fit Docking was used (Schrod̈inger Suite 2012 Induced Fit
Docking Protocol; Glide, version 5.8; Schrödinger, LLC: New York, NY,
2012; Prime, version 3.1; Schrödinger, LLC: New York, NY, 2012).
All modeling was performed within a pH range of 7.0 ± 1.0, which
encapsulates the pH at which the in vitro experiments were conducted
(i.e., pH 7.3). For the derivatives presented herein, computational
predictions showed that the pKa values of the aliphatic nitrogen atoms
range between 9.50 and 10.80 ± 1.0, while the pKa values of nitrogen
atoms that are part of the ACQ moiety range between 7.40 and 8.00 ±
1.20. Accordingly, it is plausible to assume that all aliphatic nitrogen
atoms in the ligand structures are protonated and that the aromatic
ACQ nitrogens are only partially protonated (around 50%). Thus,
simulations of ligand binding were conducted with protonated
aliphatic nitrogen atoms and neutral aromatic nitrogens. Inhibitor
docking was performed using the Glide module.51 The structures were
further refined using Glide with “refine only” option.
Considering the relative inflexibility of the steroidal core and
different conformational space of the α- and β-substituents at C(3),
differences in binding modes could be expected as well. Taking into
account the overall flexibility of the BoNT/A LC substrate cleft, it is
clear that residues in the enzyme’s substrate cleft would undergo some
additional conformational changes compared to smaller ligands. For
these reasons, the substrate cleft was slightly relaxed via Induced Fit
dockings, which was followed by Glide Grid docking. The highest
scoring models were further optimized using the OPLS2005 force field
with water as a solvent (the solvent effects were simulated using the
analytical generalized Born/surface area mode), using Polak−Ribiere
conjugate gradient with a maximum of 5000 iterations and gradient
convergence threshold of 0.05 kJ/mol. During minimization, the
backbone of the protein was constrained and the catalytic engine Zn2+
and His223, His227, and Glu262 were frozen in space. This treatment
resulted in a slightly more open catalytic cleft. Most noticeable feature
was the change in orientation of the Met253 residue. In previous
binding simulations with smaller inhibitors, it was oriented into the
binding cleft, thereby adding to the hydrophobic nature of the pocket.
Now, Met253 reorients away from the binding cleft, thus providing
enough space for the docking of a larger steroidal bis-ACQ system.
In Vitro Anti-BoNT/A LC Metalloprotease Activity.57 The
HPLC-based assay was used to evaluate small molecule mediated
inhibition of the BoNT/A LC in vitro.42 In brief, this assay utilizes an
N-terminal acetylated, C-terminal aminated synthetic peptide identical
in sequence to residues 187−203 of SNAP-25. Compounds with
intrinsic fluorescence quenching capability do not interfere with the
activity measurements of this assay because substrate hydrolysis is
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determined by HPLC separation of the products from the substrate,
followed by measurement of the peak areas. The assay mixture
contained 40 mM HEPES−0.05% Tween (pH 7.3), BoNT/A
recombinant LC, peptide substrate, 0.5 mg/mL bovine serum albumin,
and various concentrations of small molecule. The assay was run at
37 °C, quenched by the addition of TFA, and analyzed using reverse-
phase HPLC. Zinc (50 μM excess) was added to the assays to remove
compounds that are zinc chelating agents.
Percent inhibition measurements were performed in duplicate, and
standard deviations were less than 25% for all. IC50 calculations were
determined by measuring enzyme activity at nine different SMNPI
concentrations and in the absence of the small molecule. The small
molecule concentrations used in the measurements were determined
by estimating the IC50 value and moving in 1 log increments in either
direction of the estimated value. The resulting kinetic data were
subsequently fit to the Langmuir isotherm, Vi/Vo = 1/{1 + ([I]/
IC50)
h}, using nonlinear regression analysis. For Ki determination,
reaction velocity versus substrate concentration was plotted for
multiple small molecule concentrations. These plots were analyzed
using global kinetic analysis. Subsequently, the data were fit to a model
of competitive inhibition and analyzed by nonlinear regression analysis.
Primary Neuron Cell Culture. Ventral spinal cords were isolated
from day 6 embryonic chicken embryos and cultured by the method of
Kuhn58 as previously described.59 Spinal cords were removed from the
embryos and the dorsal halves trimmed away. After trypsinization for
25 min, the cells were dissociated by trituration and preplated in
Dulbecco’s modified Eagle medium for 1 h to enrich the neuronal
population by adherence of non-neuronal cells to the culture dish.
Cells remaining in suspension were centrifuged for 6 min at 1250 rpm,
resuspended in Liebowitz’s L15 medium with 10% fetal bovine serum
and N3 supplements, and plated onto six-well culture plates that were
first coated with poly-L-lysine (1 mg/mL overnight) and then with
laminin (7−10 μg/mL for 3−4 h). Neurons were incubated overnight
at 37 °C in 5% CO2 before use.
Intoxication, Inhibitor Application, and Western Blot Analysis.
Neurons were preincubated with inhibitor for 45 min. Afterward, the
cells were incubated with 10 nM BoNT/A and inhibitor for 3.5 h. The
cells were then rinsed with fresh culture medium, scraped, and
collected into tubes. The tubes were centrifuged, and supernatant was
removed and replaced with 30 μL of lysis buffer. After overnight
storage at −80 °C, the tubes were thawed, vortexed briefly, and
incubated on ice for 10 min. Lysates were centrifuged at high speed at
4 °C for 30 min to remove debris. Total protein was measured by the
Bradford assay. 12% gels were used for SDS−PAGE, and proteins were
blotted onto PVDF membranes. Western blots were probed with a
1:2500 dilution of SMI-81 anti-SNAP-25 antibody (Covance Research
Products Inc., Berkeley, CA) and 1:20000 horseradish peroxidase
(HRP) conjugated goat anti-mouse (Pierce, Rockford, IL). Western
blots were developed using a chemiluminescent substrate and imaged
with a BioRad Versadoc system. Protein bands were quantitated by
densitometry with Quantity One software (BioRad, Hercules, CA).
In Vitro Antimalarial Activity. The in vitro antimalarial drug
susceptibility screen is a modification of the procedures first published
by Desjardins et al.,60 with modifications developed by Milhous et al.,54
and the details are given in ref 47. All synthesized aminoquinolines were
screened in vitro against P. falciparum strains: CQ and MFQ susceptible
strain D6 (clone of Sierra I/UNC isolate), CQ resistant but MFQ
susceptible strain W2 (clone of Indochina I isolate), and CQ and MFQ
resistant strain TM91C235 (clone of Southeast Asian isolate).
Toxicity: Assessment of SMNPI Toxicity in a HepG2
(Hepatocellular Carcinoma) Cell Line. The compounds were
assayed for HepG2 toxicity according to protocol given in ref 47.
Toxicity: PBMC Cell Assay. Peripheral blood mononuclear cells
(PBMC) were separated from whole heparinized blood of healthy
volunteers. Blood was diluted with phosphate buffered saline (PBS)
(1:1) and layered on Histopaque solution. After centrifugation,
interface cells were collected and washed three times with PBS. After
counting, cells were resuspended in nutrient medium. Nutrient
medium was RPMI-1640 medium, supplemented with 10% fetal calf
serum (FCS), 1% glutamine (200 mM), 1% β-mercaptoethanol
(5 μM), 1% penicillin (10000 IU mL−1), and 1% streptomycin
(10 mg mL−1). Cells were seeded (200 000 cells per well) in 96-well
plates in nutrient medium with 0.5% phytohemagglutinin (PHA)
(1 mg mL−1) and different concentrations of organic compounds in
DMSO. Cells were incubated for 72 h at 37 °C in a humidified
atmosphere with 6% CO2.
Absorbances were recorded at λ = 540 and 670 nm on a recorder
(LKB 5060-006, LKB, Vienna, Austria). Absorbances corresponding to
viability of cells were obtained as A540 − A670 differences. Percent of
cell growth inhibition were calculated from formula (Asample −
Aneg.control)/(Apos.control − Aneg.control) = X and (1 − X) × 100 = % inhibition.
IC50 concentrations were defined as the concentration of a drug needed to
inhibit cell survival by 50%, compared with vehicle-treated control.
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(19) Šilhaŕ, P.; Čapkova,́ K.; Salzameda, N. T.; Barbieri, J. T.; Hixon,
M. S.; Janda, K. D. Botulinum Neurotoxin A Protease: Discovery of
Natural Product Exosite Inhibitors. J. Am. Chem. Soc. 2010, 132,
2868−2869.
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